Determination

Applications for revocation and substitution of authorisation

lodged by

Medicines Australia Limited

in respect of

the Medicines Australia Code of Conduct edition 18

Date: 24 April 2015

Authorisation numbers: A91436-A91440

Commissioners: Sims
Rickard
Schaper
Court
Featherston
Walker
Summary

The ACCC has decided to grant conditional authorisation to Medicines Australia for edition 18 of its Code of Conduct. In edition 18, Medicines Australia proposes to require its member pharmaceutical companies to report certain benefits made to individual healthcare professionals.

The ACCC has decided to impose conditions of authorisation which require:

- member companies to ensure, before providing a relevant benefit to a healthcare professional, that the benefit will be able to be individually reported
- the transparency data to be published in a common accessible format
- the transparency data to be made publicly available for at least three years from the date of first publication
- Medicines Australia to use reasonable endeavours to establish a central reporting system for reporting this transparency data and provide regular reports on its progress in doing so.

The ACCC grants authorisation for five years until 16 May 2020.

Medicines Australia Limited (Medicines Australia) represents the innovative (originator) pharmaceutical industry in Australia. Its member pharmaceutical companies provide medicines and vaccines to the Australian community.

Medicines Australia has applied for reauthorisation in respect of edition 18 of its Code of Conduct (the Code) which sets the standards for the marketing and promotion of prescription pharmaceutical products in Australia. All members of Medicines Australia must adhere to the Code, although membership of Medicines Australia is voluntary.

The Australian Competition and Consumer Commission (ACCC) has considered applications for authorisation of previous versions of Medicines Australia’s Code and the transparency regime (that is, the disclosure of payments and other transfers of value (i.e. benefits) from member companies to healthcare professionals) provided in the Code has consistently been an important issue. Most recently, in authorising edition 17 of the Code in 2012, the ACCC stated that it expected Medicines Australia to complete its intended review of transparency arrangements in the Code and to incorporate new provisions into the next edition that would facilitate greater disclosure around sponsorship and fees paid by pharmaceutical companies to individual doctors. The ACCC noted that the Code should continue to reflect community expectations about the level of transparency around these relationships. Interested parties have been advocating for this change for a number of years.

Edition 18 of the Code

Edition 18 of the Code as currently drafted introduces a new transparency regime which requires member companies to report on certain transfers of value made to individual healthcare professionals, and to identify those healthcare professionals by name, subject to the healthcare professional consenting to the disclosure. Reportable ‘transfers of value’ include: fees paid for speaking at an event, consultancy services, sitting on an advisory board or market research; and sponsorship to attend conferences and other events. Currently, under edition 17 of the Code, these transfers of value are reported at an aggregate level (e.g. by event) and do not identify the recipients.
Other key amendments in edition 18 of the Code include:

- setting a $120 (plus GST) limit on the value of each meal provided to healthcare professionals by member companies and removing reporting of such hospitality
- clarification of existing provisions in the Code regarding the nature and availability of information and claims about pharmaceutical products
- provisions regarding transparency of authorship of clinical papers
- clarification on the administration of the Code, the committees and the complaints process.

**Summary of public benefits and detriments**

The ACCC accepts that the Code provides a framework for interactions between pharmaceutical companies and healthcare professionals and that the Code is likely to result in public benefits including protecting the public from inappropriate advertising, setting consistent standards for medical and promotional material and providing the potential for greater transparency around the relationships between pharmaceutical companies and healthcare professionals. The ACCC acknowledges that, in principle, the move to individual reporting of benefits provided by member companies to healthcare professionals seems to be significant and represents an improvement over edition 17.

The ACCC also notes that the Code results in minimal detriment.

However, the ACCC’s decision to authorise conduct is discretionary and the ACCC is able to impose conditions upon authorisation. In doing so it may have regard to considerations relevant to the objectives of the *Competition and Consumer Act 2010* (the Act). In appropriate circumstances, the ACCC may impose conditions with a view to yielding a more substantial benefit or to enhance the likelihood of realisation of the public benefit. The ACCC has decided to impose a number of conditions in the reauthorisation of the Code which are discussed below.

**Member companies to report on all transfers of value made to individual healthcare professionals, and to identify those healthcare professionals by name**

As set out in its draft determination, the ACCC is concerned that edition 18 of the Code as currently drafted does not achieve an appropriate level of transparency as member companies will only publish information about a relevant transfer of value made to an individual healthcare professional where that healthcare professional consents to such information being reported. The ACCC shares the concerns of some interested parties that relevant transfers of value could be made to healthcare professionals, but not reported where the healthcare professional does not consent to the disclosure, and this significantly reduces the potential benefits of the regime. In particular, the ACCC is concerned that incomplete reporting results in a disclosure regime that cannot be relied upon as a means to disclose all potential conflicts of interest.

To address these concerns, and in order to ensure that the potential benefits from the regime are realised, the ACCC has decided to impose a condition to ensure that all relevant transfers of value by member companies to individual healthcare professionals are reported (which does not include expenditure on food and beverages) and those healthcare professionals are identified by name.

---

1 Section 91(3) of the *Competition and Consumer Act 2010* (Cth); see also Re *Medicines Australia Inc* [2007] ACompT 4 at paragraphs 106 and 126 to 134.
2 Re *Medicines Australia Inc* [2007] ACompT 4, at paragraph 126.
3 Re *Medicines Australia Inc* [2007] ACompT 4, at paragraph 128.
The condition requires member companies to take appropriate steps to ensure that, before making a transfer of value to a healthcare professional, the healthcare professional reasonably expects that the transfer will be disclosed. This approach avoids any difficulty with a consent-based approach which might arise where, as identified by Medicines Australia and other interested parties, a healthcare professional could provide consent to a transfer of value being reported, receive the transfer of value and then withdraw consent before the transfer has been reported.

The ACCC accepts that this new transparency regime is a significant change to the Code and, therefore, it is important to allow sufficient time for it to be implemented properly. Accordingly, Medicines Australia will not be required to amend the Code to require the reporting of all transfers of value until 1 October 2016. (The transparency regime originally proposed by Medicines Australia will operate from 1 October 2015 until Medicines Australia makes that amendment). To ensure that Medicines Australia and its members meet this deadline, the ACCC considers that they should prepare well in advance for the transition to reporting all transfers of value on an individual basis and should be ready to move to the new regime well before 1 October 2016. This will ensure that any unexpected events do not jeopardise the ability of Medicines Australia to meet that date and thereby satisfy this condition of authorisation.

No ongoing reporting of food and beverage expenditure

Concerns have been raised that edition 18 of the Code removes the requirement for member companies to report on food and beverage expenditure (as transfers of value to healthcare professionals) and instead, imposes a hospitality cap of $120 per meal.

In its draft determination, the ACCC considered imposing a condition requiring some form of continuing transparency around the provision of food and beverages to healthcare professionals, and posed several possible options to address this issue.

After considering further submissions following the draft determination, the ACCC has reached the view that food and beverage costs (noting the $120 cap) are secondary to the more direct transfers of value. The ACCC also recognises the significant administrative burden from ongoing reporting, particularly in the context of the move to the individual transparency regime. The ACCC therefore is not requiring Medicines Australia and its member companies to continue to report food and beverage expenditure as a condition of authorisation.

If the ACCC becomes aware that the removal of this reporting has led to significant (and unreasonable) increases in food and beverage expenditure, it may reconsider the need for reporting of this expenditure.

Central reporting system

Interested parties have supported Medicines Australia making transparency reports available to the public in the form of a searchable centralised database. Medicines Australia submits that it is actively investigating how to establish a central platform for reporting, but notes that there are a number of practical implementation issues and it will take at least two to three years to investigate and establish a database.

The ACCC considers that the development and implementation of a central reporting system should continue to be a matter of the highest priority for Medicines Australia and its members, noting the importance of providing the public with a practical way to access the individual transparency data.

The ACCC is therefore imposing a condition requiring Medicines Australia to use reasonable endeavours to develop and implement a central reporting system and to report six monthly on its website on its progress in doing so. Subject to Medicines Australia identifying any significant unanticipated issues, the new central reporting
system should be operational before Medicines Australia next seeks reauthorisation for the Code.

Subject to the findings of any Privacy Impact Assessment (PIA), the ACCC considers that the full data set should also be made available either for download from the central reporting system or separately in CSV (comma-separated values) format.\(^4\)

**Transparency reports in common format**

The ACCC considers it important that the data available from member companies’ websites, particularly prior to a centralised database being implemented, are in an appropriate common format. Accordingly, the ACCC is imposing a condition which requires member companies to report individual transparency data in CSV format so that it can be readily downloaded into a common spreadsheet format, such as Excel, which is compatible with CSV format. This is in addition to publishing the data in a searchable table format (such as PDF).

The ACCC is also imposing a condition to require that these transparency reports and the data, including data in the central reporting system once implemented, remain available on member companies’ websites for at least three years.

These three conditions will increase the likelihood of benefits to consumers, healthcare professionals and the broader public from transparency of individual transfers of value being realised where the information reported is available and accessible in an appropriate format. This will allow individuals directly accessing the data as well as other interested parties (such as healthcare professionals, consumer and healthcare professional bodies, researchers, academics and the media) to analyse the data and communicate it. This can assist consumers and the broader public to better understand the data, deter transfers of value that may raise conflicts of interest and increase confidence in the pharmaceutical industry and its interactions with healthcare professionals.

**Other issues**

In the draft determination, the ACCC sought submissions on whether to include the name of any specific drug associated with the transfer of value in the transparency reporting and whether breaches of the Code should be better publicised. The ACCC has decided not to impose conditions in this regard but expects Medicines Australia to consider these issues further in preparation for any future application for reauthorisation. In particular, during the period of this authorisation, the ACCC expects Medicines Australia to undertake a detailed consideration of how information about any specific drugs associated with particular transfers of value could be included in the transparency reporting in future. The ACCC suggests that Medicines Australia look to the approach taken in other jurisdictions where such information is reported.

Interested parties have suggested a number of other changes to the transparency reporting including reporting on research costs and Product Familiarisation Programs and applying the transparency regime across the industry more broadly. The ACCC generally accepts that it is appropriate for the new transparency model to focus on the transfers of value identified by Medicines Australia as of most concern but considers Medicines Australia should expand the reporting requirements over time as appropriate.

While the ACCC is able to impose conditions on authorisation to enhance the likelihood that the public benefits will be realised (as it proposes to do here, as outlined above), it is not for the ACCC to construct and impose its ideal or preferred system of self-regulation.\(^5\) Accordingly, the ACCC does not consider that it is appropriate for it to

---

\(^4\) CSV files stores tabular data in plain-text form.

\(^5\) Re Medicines Australia Inc [2007] ACompT 4, at paragraph 134.
require all changes proposed by interested parties to be incorporated into the Code, even if such changes may result in some level of additional public benefit.

Therefore, although interested parties have also raised concerns about other requirements under the Code, such as those dealing with Product Familiarisation Programs, sanctions, the membership of the Monitoring Committee, coverage of healthcare organisations and restrictions on advertising, the ACCC has not imposed conditions to address these issues.

The ACCC has decided to exercise its discretion to grant conditional authorisation to edition 18 of the Code until 16 May 2020.

Authorisation does not represent ACCC endorsement of a code. Rather, it provides statutory protection from court action for conduct that meets the net public benefit test and that might otherwise raise concerns under the competition provisions of the Act.
Contents

Summary.............................................................................................................................i

Contents.............................................................................................................................vi

Abbreviations & definitions.............................................................................................viii

1. The applications for authorisation .............................................................................1
   The conduct ....................................................................................................................2
   The applicant ...............................................................................................................2
   Other parties ...............................................................................................................3

2. Background ...............................................................................................................4
   Prescription medicines ..............................................................................................4
   Branded vs generic medicines.....................................................................................5
   The Code .....................................................................................................................6
   Edition 18 as drafted – existing transparency reporting to continue until 30 September
   2015 .............................................................................................................................7
   Edition 18 as drafted – new transparency reporting from 1 October 2015 .................8
   Consultation on transparency ......................................................................................11
   Transparency reporting in other jurisdictions ...........................................................12

3. Submissions received by the ACCC ..........................................................................15
   Prior to the draft determination ................................................................................15
   The draft determination ............................................................................................17
   Following the draft determination ..............................................................................17

4. ACCC evaluation .......................................................................................................20
   The future with and without ......................................................................................20
   The relevant area of competition ..............................................................................21

Supply of prescription medicines – market failures ......................................................21

Public benefit ................................................................................................................22
   i. Relationships between pharmaceutical companies and healthcare professionals ...24
   ii. Relationships between pharmaceutical companies and health consumer
       organisations and patients .....................................................................................49
   iii. Protection of public from inappropriate advertising .............................................51
   iv. Standards for medical and promotional claims ....................................................52
   v. Internal compliance procedures for pharmaceutical companies ..........................54
   vi. Administration, monitoring and enforcement ......................................................55
   ACCC conclusion on public benefits .........................................................................63

Public detriment ............................................................................................................64
   ACCC conclusion on public detriments .....................................................................65

Balance of public benefit and detriment .....................................................................65

Conditions of authorisation .........................................................................................66
   Condition 1: Reporting of all relevant transfers of value .........................................67
Condition 2: Common reporting format.................................................................70
Condition 3: Central reporting system...................................................................75
Condition 4: Public disclosure of reports and retention of records for three years....77
Condition 5: Amendment of conditions ..................................................................77

Length of authorisation.............................................................................................78

Scope of the authorisation more broadly .................................................................79

5. Determination ....................................................................................................81
   The application.......................................................................................................81
   The net public benefit test ..................................................................................81
   Conduct for which the ACCC grants authorisation.............................................82
   Date authorisation comes into effect ..................................................................82

Attachment A - Summary of relevant statutory tests ..............................................83

Attachment B – Conditions of authorisation .........................................................85
### Abbreviations & definitions

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>ACCC</td>
<td>Australian Competition and Consumer Commission</td>
</tr>
<tr>
<td>the Act</td>
<td><em>Competition and Consumer Act 2010</em></td>
</tr>
<tr>
<td>advisory board</td>
<td>a group of healthcare professionals with specific expertise contracted by a company to meet at regular intervals to provide advice on a Company’s product or group of products</td>
</tr>
<tr>
<td>AMA</td>
<td>Australian Medical Association</td>
</tr>
<tr>
<td>APNA</td>
<td>Australian Primary Healthcare Nurses Association</td>
</tr>
<tr>
<td>APPs</td>
<td>Australian Privacy Principles</td>
</tr>
<tr>
<td>ARTG</td>
<td>Australian Register of Therapeutic Goods</td>
</tr>
<tr>
<td>ASA</td>
<td>Australian Society of Anaesthetists</td>
</tr>
<tr>
<td>Cancer Voices</td>
<td>Cancer Voices Australia</td>
</tr>
</tbody>
</table>
| change of clinical significance | any change in the Product Information that is likely to alter a decision to prescribe or not to prescribe the product and may include the following:  
  a) approved indications for use  
  b) precautions for use  
  c) contra-indications  
  d) warnings  
  e) adverse effects and interactions  
  f) available dosage forms  
  g) dosage regimens and routes of administration  
  h) dependence potential  
  i) reference to special groups of patients (where necessary)  
  j) boxed warnings |
| clinical research | planned research involving humans which is designed to investigate and report upon the effectiveness (including, but not limited to pharmacokinetics, dosage regimens, routes of administration, efficacy) and/or safety (including tolerability, immunogenicity, side effect profile, drug interactions) of a medicine |
| CHF          | Consumers Health Forum of Australia |
| CMS          | Centers for Medicare & Medicaid Services |
| the Code     | Edition 18 of Medicines Australia Code of Conduct |
| Code Committee | Code of Conduct Committee |
| consultant   | an Australian healthcare professional or group of Australian healthcare professionals providing consulting services to a company in relation to specific products. For the purpose of reporting consultant services, these are regarded as different from providing advice as a member of an advisory board |

---

6 Definitions are taken from Edition 18 of Medicines Australia’s Code of Conduct.
<p>| <strong>Consumer Medicine Information</strong> | information about products written by the pharmaceutical company that makes the product. It is easy to understand and written for consumers. Companies writing Consumer Medicine Information leaflets follow guidelines to ensure the information is accurate, unbiased, and easy to understand. A separate Consumer Medicine Information leaflet is available for each prescription and many non-prescription products. |
| <strong>CSV</strong> | comma-separated values. CSV files stores tabular data in plain-text form |
| <strong>EFPIA</strong> | European Federation of Pharmaceutical Industries and Associations |
| <strong>EFPIA Disclosure Code</strong> | EFPIA HCP/HCO Disclosure Code 2014 |
| <strong>GMiA</strong> | Generic Medicines Industry Association of Australia |
| <strong>GSK</strong> | GlaxoSmithKline Australia Pty Ltd |
| <strong>the Guild</strong> | Pharmacy Guild of Australia |
| <strong>HCO</strong> | health consumer organisation |
| <strong>health consumer organisations</strong> | not-for-profit organisations that represent the interests and views of consumers of healthcare. They may range from small volunteer groups to large organisations, and generally promote views that are independent of government, the pharmaceutical industry and professional health service providers. |
| <strong>healthcare professional</strong> | a healthcare professional registered to practice in Australia who in the course of their professional activities may prescribe, dispense, recommend, supply or administer a prescription medicine in Australia |
| <strong>hospitality</strong> | the provision of food and/or beverages |
| <strong>medical representative</strong> | a person expressly employed by a company whose main purpose is the promoting of the company’s products to healthcare professionals |
| <strong>Medicines Australia</strong> | Medicines Australia Limited |
| <strong>MSD</strong> | Merck Sharp &amp; Dohme (Australia) Pty Limited |
| <strong>National Statement</strong> | National Statement on Ethical Conduct in Human Research 2007 [updated March 2014] |
| <strong>Patient Support Program</strong> | a program run by a company with or without involvement from a health consumer organisation, with the aim of increasing patient compliance and positive patient health outcomes |
| <strong>PBAC</strong> | Pharmaceutical Benefits Advisory Committee |
| <strong>PBS</strong> | Pharmaceutical Benefits Scheme |
| <strong>Pfizer</strong> | Pfizer Australia |
| <strong>PFP</strong> | Product Familiarisation Program |
| <strong>PHAA</strong> | Public Health Association of Australia |
| <strong>PIA</strong> | Privacy Impact Assessment |
| <strong>Product Familiarisation Program</strong> | a program run by the company with the aim of allowing the medical profession to evaluate and become familiar with the product following TGA registration and/or approval of new indications |</p>
<table>
<thead>
<tr>
<th><strong>post-marketing surveillance studies</strong></th>
<th>research intended to generate data on safety parameters of a product that has been approved for registration when used in accordance with the approved Product Information</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Product Information</strong></td>
<td>either the current Australian Approved Product Information or in the case of a product whose registration pre-dates the current regulatory review (‘Grandfathered Product’) the document registered is known as the ‘Full Product Information’. This Product Information must comply with the format specified in the TGA Australian Regulatory Guidelines for Prescription Medicines</td>
</tr>
<tr>
<td><strong>PSA</strong></td>
<td>Pharmaceutical Society of Australia</td>
</tr>
<tr>
<td><strong>Quality Use of Medicines</strong></td>
<td>means: selecting management options wisely; choosing suitable medicines if a medicine is considered necessary; using medicines safely and effectively</td>
</tr>
<tr>
<td><strong>RANZCP</strong></td>
<td>Royal Australian and New Zealand College of Psychiatrists</td>
</tr>
<tr>
<td><strong>RACGP</strong></td>
<td>Royal Australian College of General Practitioners</td>
</tr>
<tr>
<td><strong>registration</strong></td>
<td>the issue by the TGA of an AUST.R number for a product approved for marketing in Australia in accordance with the Therapeutic Goods Act and Regulations</td>
</tr>
<tr>
<td><strong>research and development</strong></td>
<td>any early-stage research, such as target discovery, drug discovery, mechanism of action or proof of concept studies; pre-clinical research, such as toxicological studies; and human clinical trials</td>
</tr>
<tr>
<td><strong>SAMAC</strong></td>
<td>South Australian Medicines Advisory Committee</td>
</tr>
<tr>
<td><strong>satellite meetings</strong></td>
<td>meetings held in conjunction with international or Australasian congresses and are under the auspices of the Society, College or other non-company entity in question</td>
</tr>
<tr>
<td><strong>SHPA</strong></td>
<td>Society of Hospital Pharmacists of Australia</td>
</tr>
<tr>
<td><strong>starter pack</strong></td>
<td>a small pack size of a product supplied at no cost to medical practitioners, dentists and hospital pharmacists. Starter packs are also referred to as ‘samples’ by healthcare professionals</td>
</tr>
<tr>
<td><strong>Sunshine Act</strong></td>
<td>Section 6002 of the <em>Patient Protection and Affordable Care Act</em> (Public Law No. 111-148)</td>
</tr>
<tr>
<td><strong>TGA</strong></td>
<td>Therapeutic Goods Administration</td>
</tr>
<tr>
<td><strong>Therapeutic Goods Administration</strong></td>
<td>The Division of the Commonwealth Department of Health that is responsible for the regulation of therapeutic goods in Australia</td>
</tr>
<tr>
<td><strong>TG Act</strong></td>
<td><em>Therapeutic Goods Act 1989</em></td>
</tr>
<tr>
<td><strong>therapeutic classes</strong></td>
<td>the classification system used for defining and grouping products in an approved reference manual</td>
</tr>
<tr>
<td><strong>transfers of value</strong></td>
<td>a direct or indirect transfer of value, whether in cash, in kind or otherwise. A direct transfer of value is one made by a company for the benefit of the recipient. An indirect transfer of value is one made by a third party on behalf of a company for the benefit of a recipient where the identity of the company is known to, or can be identified by, the recipient</td>
</tr>
<tr>
<td><strong>trade pack</strong></td>
<td>a package of a product which is sold by a company supplying prescription products in Australia</td>
</tr>
<tr>
<td><strong>trade display</strong></td>
<td>a display or exhibit of promotional or educational material about a product or products</td>
</tr>
<tr>
<td>the Tribunal</td>
<td>Australian Competition Tribunal</td>
</tr>
<tr>
<td>-------------</td>
<td>---------------------------------</td>
</tr>
<tr>
<td>TWG</td>
<td>Transparency Working Group</td>
</tr>
</tbody>
</table>
1. The applications for authorisation


2. The Australian Competition and Consumer Commission (ACCC) granted authorisation to Medicines Australia for edition 17 of the Code in 2012 for two years. In this time, the ACCC expected Medicines Australia to complete the work it had already commenced on increasing the level of transparency provided by the Code (such as the Transparency Working Group (TWG)) and incorporate new provisions into the next edition of the Code that would facilitate greater disclosure around sponsorship and fees paid to individual doctors.

3. Authorisation is a transparent process where the ACCC may grant protection from legal action for conduct that might otherwise breach the *Competition and Consumer Act 2010* (the Act). The ACCC may ‘authorise’ businesses to engage in anti-competitive conduct where it is satisfied that the public benefit from the conduct outweighs any public detriment. The ACCC conducts a public consultation process when it receives an application for authorisation, inviting interested parties to lodge submissions outlining whether they support the application or not. Before making its final decision on an application for authorisation the ACCC must first issue a draft determination.\(^7\)

4. On 17 October 2014, the ACCC issued a draft determination\(^8\) proposing to grant conditional authorisation for five years to Medicines Australia for edition 18 of its Code and sought submissions from the applicant and interested parties.

5. On 28 November 2014, a conference was held in relation to the draft determination to give parties the opportunity to provide further submissions (see paragraphs 83 to 84).

6. On 9 December 2014 the ACCC granted interim authorisation to Medicines Australia for the Code in terms of edition 17.\(^9\) Interim authorisation will remain in place until the date the ACCC’s final determination comes into effect or until the ACCC decides to revoke interim authorisation. Medicines Australia sought interim authorisation on the basis that it required additional time to consult further with member companies and reach a concluded position in relation to the ACCC’s draft determination; to consider any third party submissions provided to the ACCC; and to provide further submissions to the ACCC following the pre-decision conference held on 28 November 2014.

---

\(^7\) Detailed information about the authorisation process is contained in the ACCC’s Guide to Authorisation available on the ACCC’s website www.accc.gov.au.

\(^8\) Subsection 90A(1) of the Act requires that before determining an application for authorisation the ACCC shall prepare a draft determination.

\(^9\) The ACCC received submissions in support of interim authorisation from: Medicines Australia; Dr Ken Harvey; the Australian Medical Association; the Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists.
On 6 February 2015, the ACCC released revised proposed conditions of authorisation and sought further submissions from the applicant and interested parties.

The ACCC received submissions from Medicines Australia regarding the revised proposed conditions on 20 February 2015, 30 March 2015 and 9 April 2015. The ACCC sought, and on 26 March 2015 received, a response from the Australian Privacy Commissioner on potential privacy issues with the transparency reporting.

**The conduct**

The Code is a voluntary industry code of conduct which sets standards for the marketing and promotion of prescription pharmaceutical products in Australia. All member companies of Medicines Australia must adhere to the Code, although membership of Medicines Australia is voluntary.

Medicines Australia has sought reauthorisation on the basis that the Code may involve:

- a provision of a contract, arrangement or understanding which:
  - may be a cartel provision
  - may be an exclusionary provision
  - has the purpose or effect of substantially lessening competition
- conduct that may constitute exclusive dealing.

**The applicant**

Medicines Australia represents the interests of the innovative (originator) medicines industry in Australia. Its member companies supply 86 percent of the medicines that are available to Australian patients through the Pharmaceutical Benefits Scheme (PBS) (by value) (65 percent by volume) as well as providing a range of other medicines and vaccines to the Australian community. Medicines Australia states that it represents the innovative medicines industry by:

- engaging with government and other parties to develop health and industry policy
- building and maintaining relationships with government for fair reimbursement of medicines (through the PBS)
- administering the Code

---

10 Medicines Australia submission dated 16 September 2014. Excludes medical devices (such as prostheses), over the counter medicines, complimentary medicines and in-vitro diagnostic products.

• working with other health professional and consumer organisations on issues of mutual concern

• providing specialist advice to member companies and

• educating the community about industry activities.  

12. Medicines Australia’s membership is divided into four principal classes of membership:

• Class One – for research based prescription pharmaceutical companies (innovators)

• Class Two – for non-research based prescription pharmaceutical companies (generics)

• Class Three – for companies significantly engaged in research into potential pharmaceutical products but which have not yet commenced commercial production

• Class Four – being firms or companies ineligible for other classes of membership which are significantly engaged in the development, testing or registration of prescription pharmaceutical products or which are engaged with the research-based pharmaceutical industry for a significant part of their business.

13. Medicines Australia has 31 Class One members, six Class Two members, four Class Three members and 11 Class Four members.  

It is a condition of membership to any class to adhere to the Code in its entirety.

Other parties

14. Medicines Australia seeks authorisation on behalf of current and future member companies of Medicines Australia. Under subsections 88(6) and 88(10) of the Act, any authorisation granted by the ACCC is automatically extended to cover any person named in the authorisation as being a party or proposed party to the conduct, including future parties.


13 Medicines Australia supporting submission, 2 July 2014.
2. Background

Prescription medicines

15. Prescription medicines are those medicines which require a doctor’s prescription in order to access them. The supply and marketing of prescription medicines in Australia is subject to regulation designed to maintain public health and safety, and affordable access to medicines for consumers.

16. Any prescription medicine intended to be supplied in Australia must be approved and registered by the Therapeutic Goods Administration (TGA) in accordance with the Therapeutic Goods Act 1989 (TG Act). The TG Act provides a national framework for the regulation of therapeutic goods in Australia to ensure the quality, safety and efficacy of medicines and medical devices. It also sets out the legal requirements for the import, export, manufacture and supply of medicines in Australia, and includes details regarding product advertising, labelling and product appearance.\(^\text{14}\)

17. The TGA evaluates the quality, safety and efficacy of medicines and approves them before they can be supplied in Australia.\(^\text{15}\) The TGA carries out a range of assessment and monitoring activities to ensure that all therapeutic goods available in Australia are of an acceptable standard.\(^\text{16}\) All prescription medicines must be registered or listed in the Australian Register of Therapeutic Goods (ARTG) before they can be supplied in Australia.

18. All prescription medicines registered or listed on the ARTG must be accompanied with a Product Information sheet which provides a description of the characteristics of the active ingredient of the medicine, relevant clinical trials, as well as information about side effects, dosage and storage of the medicine.\(^\text{17}\)

19. The TGA issues a marketing approval letter to a pharmaceutical company when the company’s application for a particular prescription medicine to be listed or registered on the ARTG has been approved.

20. The advertising of prescription medicines is subject to a number of requirements in the TG Act, as well as the Act and other relevant laws. The TG Act prohibits the promotion of prescription medicines to the general public. Promotion to healthcare professionals is allowed under the TG Act and is regulated by the self-regulatory scheme operated by Medicine Australia through its Code.

21. One of the conditions of registration of a prescription medicine requires the promotion of all prescription medicines (whether a member or non-member of


\(^\text{16}\) See the Therapeutic Goods Act 1989.

Medicines Australia) to comply with the requirements in the relevant sections of Medicines Australia’s Code.18

22. Complaints about advertisements of prescription medicines directed to healthcare professionals are handled by Medicines Australia. If a complaint is made about the advertising activities of a non-member, the complaint is forwarded to the non-member with an invitation to have the complaint adjudicated by the Code of Conduct Committee (Code Committee). If the non-member declines, Medicines Australia may forward the complaint to the TGA or the ACCC where relevant.19

**Branded vs generic medicines**

23. Originator pharmaceutical companies compete in the development of new drugs. Pharmaceutical companies obtain patents for the development of new medicines which restrict other companies from manufacturing a copy of the medicine for the time period of the patent. Only when the patent on a medicine expires can generic versions be produced and compete with the originator brand. Even once a patent has expired branded drugs tend to sell at a premium to generics, as consumers perceive the product as in some way superior.

24. A generic medicine is a copy of a branded medicine whose patent has expired. It is chemically equivalent (bioequivalent) to its branded counterpart and must meet the same standards of quality and safety as branded drugs.

25. In 2007-08 approximately 37 percent of prescriptions dispensed on the PBS were generic drugs.20 Where there are two or more brands of the same drug listed on the PBS, each brand receives the same subsidy – up to the cost of the lowest priced brand which in many cases is a generic brand. A brand price premium paid by the consumer applies to the more expensive brand.21

26. While the promotion of branded drugs is generally directed at prescribers, generic manufacturers predominantly compete in respect of the supply of products to pharmacists. This is because consumers are offered generic drugs as a substitute to the originator brand by the pharmacist when their prescription is being filled, rather than by the prescriber. Pharmacists tend to stock the originator brand and one bioequivalent generic brand for most products. Generic manufacturers compete for wholesale supply through volume discounts and non-price benefits to have pharmacists supply their products.

27. Although membership of Medicines Australia is open to generic drug manufacturers, the majority are represented by the Generic Medicines Industry Association of Australia (GMiA). GMiA members supply over 30 percent of all

---

prescriptions dispensed under the PBS and manufacture 80 percent of all generic medicines dispensed in Australia.  

The Code

28. The Code sets standards of conduct for companies for the marketing and promotion of prescription pharmaceutical products in Australia. The Code adds to the legislative requirements of the Therapeutic Goods Regulations and the TG Act.

29. In particular, the Code specifies standards for:

- educational and promotional material directed at healthcare professionals
- company representatives
- provision of starter packs
- Product Familiarisation Programs (PFPs)
- relationship with: healthcare professionals; the general public; health consumer organisations (HCOs) and patients
- research.

30. Relevantly, the Code addresses potential conflicts of interest from unrestricted relationships between pharmaceutical companies and healthcare professionals, which may harm consumers, for example, through the risk of inappropriate prescribing by healthcare professionals. A key feature of the revised Code is the reporting of individual payments and other transfers of value provided to healthcare professionals.

31. Edition 18 of the Code introduces a new transparency regime which requires member companies to report on certain transfers of value made to individual healthcare professionals, and to identify those healthcare professionals by name, where the individual has given consent to this disclosure. The regime is outlined in more detail below.

32. Other amendments include:

- setting specific limits on the value of food and beverages provided to a healthcare professional by member companies
- clarification of existing provisions in the Code regarding the nature and availability of information and claims
- provisions regarding transparency of authorship of clinical papers
- clarification on the administration of the Code (in particular the roles of the Monitoring Committee) and the complaints process.

Edition 18 as drafted – existing transparency reporting to continue until 30 September 2015

33. Under edition 18 of the Code, in the period up until 30 September 2015, member companies will continue to comply with existing reporting requirements.\[23\]

34. These requirements include reporting on:

- payments made to healthcare professional consultants and advisory board members in respect of: consultancy fees, sitting fees, honoraria, chair person’s fee or similar; hospitality; accommodation; and travel
- educational meetings and symposia held or sponsored by that company for each month of the financial year at six month intervals. The reporting table must include:
  - details of sponsorship (registration fees, costs of accommodation and travel) of healthcare professionals or non-healthcare professionals to attend any educational event
  - details of any payments (fees, registration costs, costs of accommodation and travel) to speakers to attend and give a presentation at an educational meeting.

35. This information is currently provided in the following reports:

- Summary of Events Sponsored by Member Companies – including:
  - total sponsorship paid for each educational event or meeting and the total number of recipients and
  - total amount paid in fees to speakers for each educational event or meeting and the total number of speakers receiving payment.
- Summary of Advisory Boards Convened by Member Companies – for each advisory board, reporting of the details, the number of members, honoraria/sitting fees, costs of any hospitality/accommodation/travel, venue details and any third party costs
- Summary of Health Professionals Consultancies Engaged by Member Companies – including total consultancies for the year, the cost of fees, the number of consultants and the cost of any hospitality/accommodation/travel
- Summary of Health Consumer Organisation Support by Member Companies (this report is retained under the new transparency regime) – including the name of the HCO and the support provided.

\[23\] See section 41.2 of the Code. See in particular: section 41.2.1; section 41.2.2.
36. The new transparency regime imposes a general obligation upon member companies to report the transfers of value identified in section 41.3.1 of the Code (related to prescription medicines only), namely:

- fees paid to healthcare professionals for speaking at an educational meeting or event
- sponsorship of a healthcare professional to attend an educational event (e.g. airfares, accommodation or registration fees associated with the meeting (whether held within or outside Australia))
- fees paid to healthcare professional consultants in Australia for consultancy services provided in relation to, for example, educational meetings, preparation of promotional materials or product position papers, assistance with training or any other advice to the company but excluding research and development work and clinical trials (e.g. payments in respect of consulting fees, accommodation and airfares (both within and outside Australia))
- fees paid to healthcare professionals for the purposes of market research where the identity of the healthcare professional is known to the member company.

37. Section 41.3.1 of the Code requires the following information to be reported for each relevant transfer of value:

- the date of the event or provision of the services
- the healthcare professional’s name
- the type of healthcare professional (e.g. medical practitioner, pharmacist, nurse practitioner)
- the healthcare professional’s principal practice address
- a description of the service (e.g. speaker, Advisory Board member, Chairperson at educational event meeting etc)
- a description of the event (e.g. company sponsored/independent meeting held in Australia/overseas)
- whether the payment was made to the healthcare professional, the healthcare professional’s employer or another entity (such as a charity)
- the amount of the payment or transfer of value, subdivided into (where relevant) registration fees, travel and accommodation and fees for service.

---

24 See section 41 of the Code which also cross references other sections of the Code, in particular section 9. The Introduction also outlines the importance of transparency.
38. The Code Guidelines will include a template to be used by companies when making such reports.

39. As noted, transfers of value in respect of the provision of food and beverages will no longer be reported in most cases. However the Code:  
   
   • continues to require that any meals or beverages offered by companies to healthcare professionals are secondary to the educational content and not excessive 
   
   • introduces a new requirement that the maximum cost of a meal and beverages provided by a member company to a healthcare professional within Australia must not exceed $120 (excluding GST and gratuities). Under the Code, this maximum would only be appropriate in exceptional circumstances and in the majority of circumstances, the cost of a meal and beverages should be well below this figure.

40. From 1 October 2015, member companies will separately report on sponsorship of educational meetings and symposia organised by third party organisations. For example:
   
   • financial sponsorship of a third party educational event 
   
   • monetary contribution to support the conduct of institutional grand rounds, clinic meetings or journal club meetings 
   
   • purchasing space to provide a trade display at an educational event (including if this is the only sponsorship of an event).

41. If a company provides nothing directly to healthcare professionals other than food and beverages for an educational meeting (whether run by a member company or a third party organisation) then this information is not directly reportable (although the $120 limit per meal applies).

42. From 1 October 2015, transparency data will be produced by each member company in the following reports:
   
   • HCP Aggregate Transfer of Value Report – a new report, containing details of individual transfers of value to healthcare professionals. A template will be provided in the Code Guidelines (a draft template was provided with the application).
   
   • Sponsorship of Third Party Educational Meetings and Symposia – based on the existing ‘Summary of Events Sponsored by Member Companies’ report
   
   • Summary of Health Consumer Organisation Support by Member Companies – report retained from the existing reporting regime.

43. The Code requires each member company to publish the HCP Aggregate Transfer of Value Reports on its own website (with hyperlinks available on the Medicines

---

25 See section 9.4.3 of the Code.
26 See section 41.3.5 of the Code.
Australia website) for two years from the date of first publication. The most senior executive officer of the member company must verify the report. The initial HCP Aggregate Transfer of Value Reports covering the period 1 October 2015 to 30 April 2016 must be published no later than 31 August 2016 and every six months thereafter.

44. The Third Party Educational Meetings and Symposia report (using the template in the Code Guidelines) and the Summary of Health Consumer Organisation Support by Member Companies report will be published on the Medicines Australia website. The Sponsorship of Third Party Educational Meetings and Symposia reports must be provided to Medicines Australia within four months for each six month period ending on 30 April and 31 October (the first report will be for 1 October 2015 to 30 April 2016). The Summary of Health Consumer Organisation Support by Member Companies reports must be provided to Medicines Australia on an annual basis by 30 April each year. Medicines Australia will publish these reports within two months of the date on which reports must be submitted.

45. Medicines Australia advises that it and its member companies are actively investigating the establishment of a central platform for future disclosure of individual transfers of value. Medicines Australia notes that there are outstanding issues to consider (outlined at paragraph 204).

Informed consent

46. As noted above, edition 18 obliges member companies to report all relevant transfers of value to healthcare professionals; however section 41.3.2 of the Code requires that member companies establish a means to ensure informed consent and maintenance of records which comply with Australian privacy legislation.

47. Prior to the draft determination, Medicines Australia explained that this means that member companies cannot report individual transfers of value made to healthcare professionals, where the healthcare professional has not consented to disclosure of the transfer. In these circumstances, these transfers would be reported in aggregate by each member company, along with the number of recipients, but without details of the healthcare professionals to whom they were made.

48. Medicines Australia submitted that these provisions of the Code reflect the need for its members to comply with Australian privacy legislation in relation to the reporting of individual healthcare professional personal information.

49. In the draft determination, the ACCC noted that, under edition 18 of the Code, member companies would be able to make transfers of value to healthcare professionals, but not report them where the healthcare professional did not subsequently consent to that reporting. The ACCC was concerned that this does not achieve an appropriate level of transparency as the data is likely to be incomplete. The ACCC therefore proposed a condition to ensure that all relevant transfers of value by pharmaceutical member companies to individual healthcare professionals are reported (discussed further under Healthcare professionals’ consent at paragraphs 133 to 163 below).

---

27 See section 41.3 of the Code.
Consultation on transparency

50. In August 2012, Medicines Australia established the TWG (following submissions concerning edition 17 of the Code). The TWG’s aim was to identify measures and policies to further enhance transparency surrounding transfers of value between healthcare professionals and the pharmaceutical industry.

51. The TWG participants were drawn from a cross-section of the Australian health sector, which included member companies and a diverse range of health professional and consumer groups.

52. In June 2013, the TWG released a model for introducing greater transparency, which is outlined in its Transparency Model Consultation and Discussion Paper to aid discussion and facilitate submissions on the transparency provisions to be included in edition 18 of the Code (it should be noted that there was not consensus on all of the recommendations in the TWG’s model).

53. Medicines Australia submits that it undertook substantial engagement with member companies, the health sector and the broader community in developing the proposed transparency model in the Code (including inviting submissions to the Code Review from 250 stakeholders, issuing a media release concerning the review, consumer workshops, stakeholder forums and meetings). In addition, for the first time representatives from the consumer and healthcare professional sectors were members of Medicines Australia’s Code Review Panel. Medicines Australia submits that it received over 80 submissions and met with a number of relevant parties, and 39 people attended the consumer workshops.

54. Medicines Australia in consultation with its Code Review Committee revised the transparency reporting (as summarised above). These changes (along with other changes from edition 17 to edition 18 of the Code) were adopted by Medicines Australia’s members on 17 June 2014.

55. The transparency regime proposed by Medicines Australia is broadly consistent with the proposal of the TWG in its Consultation and Discussion Paper insofar as it provides for the individual disclosure of benefits provided by member companies to healthcare professionals. However, some proposals of the TWG have not been directly adopted in the transparency model proposed by Medicines Australia. For example the TWG proposed:

- the new regime commence on 1 January 2015
- reporting of all transfers of value above a certain threshold (e.g. $25, or $10 if the total transfers to the healthcare professional in that calendar year exceeds $100)
- continued reporting of food and beverage costs
- inclusion of all travel costs in travel and accommodation reporting (such as taxis, parking and ground transfer costs, in addition to flights).

56. The TWG did not comment on whether healthcare professionals should have the option to receive a transfer of value without it being individually reported. This may be because it assumed that any reporting regime would be universal.
57. The TWG did not agree on whether other educational function costs (such as audio-visual and room hire costs) should be allocated as a transfer of value to healthcare professionals.

**Transparency reporting in other jurisdictions**

**European Federation of Pharmaceutical Industries and Associations model**

58. Medicines Australia submits that its transparency model adopts a similar approach to that of the European Federation of Pharmaceutical Industries and Associations (EFPIA) HCP/HCO Disclosure Code (EFPIA Disclosure Code).

59. The EFPIA Disclosure Code is an activity based model where transfers of value provided by its member companies to healthcare organisations and professionals are recorded and categorised by activity. The EFPIA reporting focuses on significant transactions such as donations and grants (healthcare organisations only), payments for consultancies, and contributions to costs related to events (excluding meals and drinks).

60. All EFPIA member companies are required to incorporate the EFPIA Disclosure Code into their national codes in full. Where a provision of the EFPIA Disclosure Code conflicts with applicable national laws or regulations, deviations are allowed, but only to the extent necessary to comply with the national law or regulation.

61. The databases for reporting transfers of value will operate at a national level with each EFPIA member company able to decide how to present its transfer of value data. The first reporting period under the EFPIA Disclosure Code will be the 2015 calendar year, with the first reports released in 2016.

62. The EFPIA Disclosure Code stipulates that the disclosure of transfers of value by each member company shall be on an individual basis, subject to ‘legal reasons’, in which case amounts shall be disclosed on an aggregate basis. In particular, Member Companies must comply with applicable data protection and other laws, which must be checked at a national level by EFPIA members prior to any

---


31 See sections 3.01 and 3.02 of the EFPIA Disclosure Code 2014.
disclosure. Companies are encouraged to obtain consent from healthcare professionals.\textsuperscript{32}

\textbf{USA Sunshine Act}

63. Some members of the TWG considered that the Sunshine Act (Section 6002 of the \textit{Patient Protection and Affordable Care Act} (Public Law No. 111-148))\textsuperscript{33} provides a better model of transparency. The Sunshine Act requires pharmaceutical and medical device manufacturers to report payments and transfers of value given to physicians and teaching hospitals.\textsuperscript{34} Certain payments and transfers of value are exempt from reporting, such as: payments for speakers and faculty at certain accredited continuing medical education events; food and beverage provided to attendees of a large scale conference or meeting if the cost of each individual covered recipient’s meal is not separately identifiable; product samples not intended to be sold and intended for use by patients; educational materials for use by or with patients; payments or transfers of less than $10 in value, unless they exceed $100 per year for an individual professional.\textsuperscript{35}

64. Manufacturers of pharmaceutical and medical devices are required to report to the Centers for Medicare & Medicaid Services (CMS) (the agency responsible for implementing the Sunshine Act) identifying information about the physician to whom the payment was made, including their name, business address, specialty, National Provider Identifier number and license number, the nature and amount of the payment or transfer, and any explanatory details. Where applicable, the name of the manufacturer’s product related to the payment or transfer will also be reported. The Sunshine Act required manufacturers to commence collecting data as of August 2013, with release of the first public report scheduled for 30 September 2014.

65. Before the data is released publicly the Sunshine Act allows a 45 day period to review and dispute the data. Following technical issues with the online transparency reporting database in August 2014, CMS extended the dates for physicians and teaching hospitals to review the data for accuracy to 8 September 2014.\textsuperscript{36}

66. On 30 September 2014, CMS released the data from the last five months of 2013 on its Open Payments database. The data contains 4.4 million payments valued at nearly US$3.5 billion attributable to 546,000 individual physicians and almost 1,360


\textsuperscript{33} The Sunshine Act was passed as part of the Patient Protection and Affordable Care Act (health care reform) in 2010.

\textsuperscript{34} The categories of transfer of value are: consulting fees; compensation for services other than consulting; honoraria; entertainment; meals; travel expenses; education; research; charitable contributions; royalty or licence; current or prospective ownership or investment interest; direct compensation for serving as faculty; as a speaker for a medical education program; grants.

\textsuperscript{35} These amounts are increased annually by CPI from 2012.

teaching hospitals. Future reports will be published annually and will include a full 12 months of payment data, beginning in June 2015.  

67. In this first report, about 40 percent of the records published were de-identified. In cases where CMS was unable to match the physician information or the record was not available for review and dispute but the company had attested that the payment had been made, the personally-identifiable information was suppressed temporarily in the record.  

---

37 CMS, CMS makes first wave of drug & device company payments to teaching hospitals and physicians public, media release, 30 September 2014.  
38 CMS, CMS makes first wave of drug & device company payments to teaching hospitals and physicians public, media release, 30 September 2014.
3. Submissions received by the ACCC

68. The ACCC tests the claims made by the applicant in support of an application for authorisation through an open and transparent public consultation process. The ACCC aims to consult extensively with interested parties that may be affected by the proposed conduct to provide them with the opportunity to comment on the application.

69. The ACCC invited submissions from over 200 interested parties potentially affected by the applications for reauthorisation. The ACCC received submissions from 59 interested parties, including pharmaceutical companies,39 industry associations,40 Government departments,41 and other groups.42 The ACCC also received a number of submissions from individuals,43 including separate submissions from 25 individuals44 (referred to throughout this submission as 25 Individuals) which were based on a common petition. The views of Medicines Australia and interested parties are summarised below.

Prior to the draft determination

Medicines Australia

70. Broadly, Medicines Australia submits that edition 18 of the Code will, like edition 17, provide the benefits of a strong, voluntary industry code. The significant amendments made in edition 18 of the Code will make it an even stronger vehicle for providing greater transparency regarding the industry and greater stakeholder confidence in the industry. Medicines Australia also notes that the number of complaints received by its Code Committee has been progressively decreasing. Medicines Australia submits that the effect of edition 18 is to greatly enhance the

39 Merck Sharp & Dohme (Australia) Pty Limited; GlaxoSmithKline Australia Pty Ltd; Pfizer Australia; Sanofi-Aventis Australia Pty Ltd; Novo Nordisk Pharmaceuticals Pty Ltd; Celgene Pty Ltd; Bristol-Myers Squibb Australia.
40 The Royal Australian and New Zealand College of Psychiatrists; the Pharmacy Guild of Australia; the Australian Primary Healthcare Nurses Association; the Society of Hospital Pharmacists of Australia (in submissions prior to and after the draft determination); the Australian Society of Anaesthetists; the Royal Australian College of General Practitioners; the Pharmaceutical Society of Australia Ltd; the Australian Medical Association; the Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists (submission on interim authorisation).
41 The Department of Health; the South Australian Medicines Advisory Committee; the Australian Privacy Commissioner.
42 CHOICE; the Consumers Health Forum; Cancer Voices Australia; Therapeutic Guidelines Limited; the Public Health Association of Australia.
43 Dr Ken Harvey; Mr Geoff Kirwood; Professor Philip Morris; Professor Ian Haines; Mr Shane Carney; Ms Alison Marcus; Dr Geoff Smith; Dr Rob McEvoy; Mr Chris Del Mar; Associate Professor Richard O’Brien.
44 Dr Stuart Anderson; Professor Jon Jureidini; Ms Kerry Holmes; Mr Robin M G Brown; Mr Peter J Bayly; Professor Joel Lexchin; Mr John T D Wood; Ms Margot Murphy; Mr Dan Kent; Dr Mary Osborn; Mr John Braithwaite; Mr Ross Gubbels; Mr Peter Sainsbury; Mr Sean Israel; Ms Roseanne Peel; Professor Alistair MacLennan; Professor Marcello Costa; Mr Jarrod McMaugh; Dr Tim Woodruff; Dr Elissa Campbell; Professor Peter Schönholzer; Associate Professor Barbara Mintzes; Dr Robert Purssey; Dr Agnes Vitry; Ms Nikita Kotlarov.
existing public benefits that flow from the Code and result in minimal public
detriment.

71. Medicines Australia submits that edition 18 of the Code incorporates new
amendments to transparency reporting that focus on key interactions between
member companies and individual healthcare professionals and facilitate greater
disclosure. The amendments aim to maintain community confidence in the value of
interactions between member companies and healthcare professionals.

72. Medicines Australia submits that the other amendments to the Code also
strengthen the public benefits of the Code. For example, amendments to sections
of the Code relating to advertising to the general public, standards for medical and
promotional claims, relationships between pharmaceutical companies and third
parties and healthcare professionals, and monitoring and complaints.

Interested parties

73. One of the key issues raised in submissions is the new transparency regime
introduced in edition 18 of the Code. In principle, most interested parties are
supportive of individual disclosure of transfers of value to healthcare professionals.

74. Merck Sharp & Dohme (Australia) Pty Limited (MSD), GlaxoSmithKline Australia
Pty Ltd (GSK), Pfizer Australia (Pfizer), Therapeutic Guidelines Limited and the
Australian Medical Association (AMA) support the revisions to the Code and
reauthorisation, particularly the changes to transparency reporting.

75. A number of submissions consider that Medicines Australia’s proposed model will
not provide the level of transparency anticipated (and is not consistent with the
TWG’s recommendations) and thus will not increase the public benefits of the
Code. Of particular concern is that healthcare professionals can withhold their
consent to publish their information.

76. CHOICE, the Consumers Health Forum of Australia (CHF), Cancer Voices
Australia (Cancer Voices), the Royal Australian College of General Practitioners
(RACGP), Dr Harvey, Mr Kirwood, Professor Morris, Professor Haines and 25
Individuals do not support authorisation on the basis that the changes to the
transparency reporting are flawed.

77. A number of interested parties suggest further changes to enhance the
transparency regime. For example, expanding the transparency reporting to
include various other transfers of value (for example research and development,
Patient Support Programs, food and beverages, venue costs, transfers not related
to prescription pharmaceuticals, and transfers to medical practices) and that the
drug name should be reported. A number of parties also consider there should be
an accessible centralised database for reporting.

78. Other key issues raised by interested parties were in relation to Patient Support
Programs, PFPs/starter packs, membership of the Monitoring Committee,
promotional materials, market research, ghost writing, clinical trials/scientific

---

45 The Royal Australian and New Zealand College of Psychiatrists; the Pharmacy Guild of
Australia; the South Australian Medicines Advisory Committee; the Australian Primary
Healthcare Nurses Association; the Society of Hospital Pharmacists of Australia; the Australian
Society of Anaesthetists; the Department of Health; the Pharmaceutical Society of Australia.
research, sanctions under the Code and coverage of healthcare organisations/employer organisations under the Code.

79. Interested parties also note that there are a number of pharmaceutical companies (as well as Australian health professional organisations) that are not subject to the Code and associated transparency reporting.

The draft determination

80. On 17 October 2014, the ACCC issued a draft determination proposing to grant conditional authorisation for five years to Medicines Australia for edition 18 of its Code. The ACCC proposed to impose a condition to ensure that all relevant transfers of value by member companies to individual healthcare professionals are publicly reported.

81. The ACCC also identified that there may be merit in including some form of continued reporting of food and beverages provided by member companies to healthcare professionals.

82. The ACCC sought submissions on these and other issues, including:

- whether the transparency reporting should include the relevant drug name
- the practical issues and timing for implementing a central reporting system
- whether important decisions should be circulated in the form of a media release.

Following the draft determination

83. A pre-decision conference was requested by the RACGP to discuss the draft determination. The conference was held in Canberra on 28 November 2014 with video conferencing facilities to other locations. A record of the conference may be obtained from the ACCC’s public register at: www.accc.gov.au/authorisationsregister.

84. The primary issues discussed at the conference were:

- the proposed condition of authorisation, including the issue of healthcare professionals withdrawing consent after receiving a transfer of value, and Medicines Australia’s request to delay implementing the condition
- food and beverage reporting
- implementing a centralised database for reporting the transparency data

---

46 The conference was attended by representatives of Medicines Australia, the RACGP, Novartis Group, Novo Nordisk, the AMA, the Royal Australian and New Zealand College of Ophthalmologists, the CHF, the Public Health Association of Australia, and Professor Philip Morris.
• the length of time that the transparency data should remain published.

85. In addition, the ACCC received further written submissions in response to the draft determination from Medicines Australia and a number of interested parties.

86. The submissions from interested parties generally support the condition proposed in the draft determination.

87. Medicines Australia indicated that it is prepared to accept the proposed transparency condition subject to the deadline for complying with the condition being extended to 1 October 2016. The AMA, Sanofi, Celgene, Novo Nordisk, Novartis, Pfizer and Bristol-Myers Squibb also support a delay until 1 October 2016. The RACGP, the Public Health Association of Australia (PHAA), the CHF, Professor Morris and Dr Harvey do not support a delay.

88. Medicines Australia and the AMA query how the proposed condition would affect the ability for a healthcare professional to withdraw their consent to disclosure after receiving a transfer of value. The PHAA, Professor Morris, the CHF and the RACGP also commented on this issue.

89. Medicines Australia opposes a condition requiring ongoing food and beverage reporting submitting that it would be burdensome and unnecessary, given that the new transparency regime captures key data and is more meaningful for consumers. Professor Morris, Sanofi, Novo Nordisk, Celgene and Pfizer support this view. Dr Harvey, the RACGP, the CHF, the SHPA (Society of Hospital Pharmacists of Australia), the PHAA and Associate Professor Richard O’Brien support some form of ongoing reporting.

90. Medicines Australia advises that it will take two to three years to investigate and build an effective centralised reporting database, noting that there are outstanding issues. Pfizer, the RACGP, the PHAA, the CHF and the Royal Australian and New Zealand College of Psychiatrists (RANZCP) consider that a centralised database is valuable. The RACGP and the SHPA submit that data should remain published for longer than two years.

91. Medicines Australia submits that it is neither necessary nor appropriate to require a press release in respect of certain breaches of the Code. However Dr Harvey, the CHF and the PHAA support such press releases.

92. Medicines Australia and Dr Harvey support excluding research and development from the transparency reporting, however Dr Smith and Mr Kirwood continue to have concerns.

93. Medicines Australia submits that it is not appropriate to name specific medicines in the transparency reports. Sanofi, Novo Nordisk, Celgene, Pfizer and MSD support this view. Cancer Voices, the PHAA, the CHF and Dr Harvey submit that the drug name should be included in the individual reporting where relevant.

94. More generally, Medicines Australia submits that given the significant public benefits arising from the new Code, unduly onerous conditions do not sit well with principles of good regulation nor ‘cutting red tape’.

95. Sanofi recommends the broader application of the Code to all pharmaceutical companies.
96. In February 2015, the ACCC consulted with Medicines Australia and interested parties on five revised proposed conditions of authorisation (February consultation). The submissions received are discussed under *Conditions of authorisation*.

97. The views of Medicines Australia and interested parties are considered in detail in the evaluation chapter of this determination. Copies of public submissions may be obtained from the ACCC’s website [www.accc.gov.au/authorisationsregister](http://www.accc.gov.au/authorisationsregister).
4. ACCC evaluation

98. The ACCC’s evaluation of edition 18 of the Code is in accordance with the relevant net public benefit tests contained in the Act. While there is some variation in the language of the tests, in broad terms, the ACCC is required to identify and assess the likely public benefits and detriments, including those constituted by any lessening of competition, and weigh the two.

99. In broad terms, the ACCC may grant authorisation if it is satisfied that the benefit to the public would outweigh the public detriments.

The future with and without

100. To assist in its assessment of the conduct against the authorisation tests the ACCC compares the likely future with the conduct that is the subject of the authorisation to the likely future without the conduct that is the subject of the authorisation. The ACCC will compare the public benefits and detriments likely to arise in the future where the conduct occurs against the future in which the conduct does not occur.

101. Neither Medicines Australia nor any interested party commented on what the most appropriate likely future without would be.

102. The current authorisation of edition 17 of the Code was due to expire on 11 January 2015. As noted above, the ACCC has granted interim authorisation for the Code in terms of edition 17 until the date the ACCC’s final determination comes into effect or until the ACCC decides to revoke interim authorisation.

103. Absent reauthorisation (and upon revocation of the interim authorisation) neither edition 17 nor edition 18 of the Code will have statutory protection. The ACCC considers that the most likely future without the conduct that is the subject of the authorisation is that a modified version of the Code would operate. In circumstances in which it would not have statutory protection from legal action under the Act, Medicines Australia may decide not to include detailed provisions in that code dealing with such matters as:

- regulating member relationships with healthcare professionals which impose limits and restrictions on the provision of information and promotional materials, educational meetings, research activities and the provision of benefits such as sponsorship and hospitality

- providing for disciplinary measures.

104. Relevant legislation would continue to apply. The Act and relevant state and territory fair trading legislation contain general consumer protection provisions (but these are not pharmaceutical specific) and the TGA regulates the advertising and promotion of pharmaceutical products to the public.

105. As found by the Australian Competition Tribunal (the Tribunal), absent the conduct that is the subject of the authorisation, the provision of benefits to healthcare

47 Subsections 90(6), 90(7), 90(5A) and 90(5B), 90(8) of the Act. The relevant tests are set out in Attachment A.
professionals by pharmaceutical companies are likely to be less regulated. While a culture of restraint and sensitivity to public criticism may moderate the development of the practice of conferring benefits to healthcare professionals, there is a real chance that, absent any mechanism for their limitation (and scrutiny), some companies (and doctors) would break out of that culture, and the conferring of benefits may take new and more subtle forms.48

The relevant area of competition

106. Medicines Australia submits that the relevant market is that for the supply of prescription medicines in Australia. No other party made submissions on the relevant area of competition likely to be affected by the Code.

107. The ACCC notes that the Code regulates the activities surrounding the promotion of prescription products on an industry-wide basis across all classes of prescription medicines. The ACCC recognises that not all prescription medicines are substitutable for one another and considers that there are likely to be individual product markets for different types and/or classes of drugs. However, the ACCC does not consider that a precise definition of the market is necessary for the assessment of the Code.

Supply of prescription medicines – market failures

108. The ACCC recognises that the supply of prescription medicines is subject to ‘market failures’ which are common to many parts of the health sector:

- The principal agent problem – the patient (principal) engages a healthcare professional (agent) because the patient does not have the expert knowledge required to diagnose and treat their condition. To the extent that the objectives of the patient and the healthcare professional differ (including as a result of a conflict of interest), market failure may occur because the patient is unable to properly observe the healthcare professional’s objectives or evaluate their actions owing to the information asymmetry between them.

- Information asymmetry – exists in markets where one party in a transaction knows a material fact that the other does not. Given the complexity of the products, Medicines Australia’s members may have the ability and incentive to take advantage of their greater information advantage over patients and healthcare professionals.

- Behavioural bias and conflict of interest – healthcare professionals like other consumers are prone to biases that may be exploited by sellers of goods and services. These include excessive risk aversion and placing greater weight (consciously or subconsciously) on options that are easy to understand or presented in a manner that is ‘educational’ rather than promotional. Medicines Australia members may have the ability and incentive to exploit the behavioural biases of healthcare professionals and in turn influence their decisions in terms of the treatment

48 Re Medicines Australia Inc [2007] ACompT 4, at paragraph 314.
recommended and the particular drugs prescribed. In particular, there are concerns that where healthcare professionals are receiving transfers of value from pharmaceutical companies, their professional judgement or actions may be affected or compromised in choosing a treatment for a patient.

- Bounded rationality – some healthcare professionals and patients may lack the training and capacity to understand all the relevant information held by pharmaceutical companies. Even those healthcare professionals with relevant training may be time poor and unable to process the relevant information comprehensively and may rely on information provided by pharmaceutical companies. Given the complex nature of the relevant products, Medicines Australia’s members may have the ability and incentive to engage in various practices that exploit the bounded rationality of patients, healthcare professionals and other third parties.

109. The ACCC notes that the following matters are also relevant to the supply of prescription medicines:

- the PBS regulates the price paid by the public for most prescription medicines
- advertising of prescription medicines to members of the public is prohibited by law
- the sale of prescription medicines is dependent upon the decisions of medical practitioners about which medicines they prescribe. Members of the public cannot purchase prescription medicines unless they have been prescribed by a healthcare professional and are reliant upon the healthcare professional’s expertise and judgement to prescribe the medicine most appropriate to them
- aside from the TG Act (which primarily regulates advertising of prescription medicines to the public), there is no specific regulation under Commonwealth, state or territory law of the ways in which prescription medicines can be advertised and promoted to healthcare professionals.

Public benefit

110. Public benefit is not defined in the Act. However, the Tribunal has stated that the term should be given its widest possible meaning. In particular, it includes:

…anything of value to the community generally, any contribution to the aims pursued by society including as one of its principal elements … the achievement of the economic goals of efficiency and progress.\(^\text{49}\)

111. Medicines Australia submits that the Code provides significant benefits to the public. Medicines Australia notes the provisions of the Code:

- effectively regulate interactions between member companies and healthcare professionals (noting the significant changes to the transparency reporting)
- ensure high, consistent and industry-specific standards for medical and promotional claims
- effectively protect the public from being exposed to inappropriate advertising
- deal with interactions between member companies, patients and other third parties
- require internal company training and compliance
- cover the effective administration of the Code and the complaints process, and the proactive reviews of the Monitoring Committee.

112. Medicines Australia submits that it and its member companies are proud of their role in setting the standards for ethical conduct and transparency in Australia. Medicines Australia further submits that edition 18 of the Code achieves an appropriate balance between increased transparency regarding the industry and greater stakeholder confidence in the industry and a regime that is workable and effective because it has broad based support.

113. The ACCC’s assessment of the likely public benefits from the provisions of the Code along with the key submissions of interested parties follows under the following headings:

   i. Standards for and disclosure of the relationships between pharmaceutical companies and healthcare professionals, including reporting transfers of value and standards for other interactions
   ii. Relationships between pharmaceutical companies and health consumer organisations and patients
   iii. Protection of the public from inappropriate advertising
   iv. Standards for medical and promotional claims
   v. The requirement that pharmaceutical companies have an internal compliance procedure promoting compliance by all company employees
   vi. Administration, monitoring and enforcement.

114. Consistent with the view of the Tribunal, the ACCC notes that it is not for the ACCC to construct and impose its ideal or preferred system of self-regulation. However it may impose a condition to yield a more substantial public benefit or to enhance the likelihood that the public benefit will be realised. The ACCC’s evaluation below is consistent with this approach.

---

50 Re Medicines Australia Inc [2007] ACompT 4, at paragraph 134.
i. Relationships between pharmaceutical companies and healthcare professionals

115. Medicines Australia submits that the Code continues to strictly limit the circumstances in which benefits may be provided to healthcare professionals in order to ensure there is no inappropriate influencing of healthcare professionals by member companies. Amendments in edition 18 include:

- companies must have policies and procedures in place that will ensure that member companies adhere to existing and new Code requirements including the maximum cost of a meal
- a meal in Australia must not exceed $120 (plus GST and gratuities) per healthcare professional
- travel may only be provided if it is provided in direct association with the educational event and must be by the most practical direct route
- clarification that financial sponsorship of an independent educational event must be paid to the organisation arranging the event (not an individual healthcare professional)
- the amount paid to an educational meeting organiser for a trade display must be reported in accordance with the new sponsorship of independent educational meetings report.

116. The ACCC accepts that the relationship between healthcare professionals and pharmaceutical companies is an important one and that transfers of value made by companies to healthcare professionals in appropriate circumstances are legitimate.

117. However the ACCC considers that unrestricted relationships between pharmaceutical companies and healthcare professionals, particularly where there is some form of benefit provided to healthcare professionals, result in potential conflicts of interest and inappropriately influences prescribing practices. As noted by the Tribunal:

…detriment lies in the effect that such conduct may have upon the prescribing practices of healthcare professionals directly influenced by it or by the views of professional opinion leaders who have links to particular companies. If the prescribing practices of healthcare professionals are influenced directly or indirectly by sympathies for particular products because of benefits derived from or links to the manufacturer or distributor of those products, patient care may be compromised. Patients in need of treatment will not necessarily be provided with that which is best for them. In an indirect sense there is also an anti-competitive detriment to the extent that key decisions in the relevant market may be affected by factors extraneous to the quality of the product and its cost.

---

51 Edition 18 of the Code initially included this clause only in the educational event section of the Code at 9.4.3. However Medicines Australia has agreed to clarify in the Code that the cap applies to any meals provided to healthcare professionals (for example, in relation to consultancies or advisory boards).
52 Section 9 of the Code. In particular: section 9.3; sections 9.4.3, 9.7.7; sections 9.4.4, 9.7.5; section 9.5.1; section 9.6.5.
53 Re Medicines Australia Inc [2007] ACompT 4, at paragraph 315.
Accordingly, the ACCC sees public benefit in the continued regulation by the Code of the benefits which can be provided by member companies to healthcare professionals and the circumstances in which they can be provided.

The ACCC also considers that there is a benefit in providing an appropriate dollar cap on hospitality provided by member companies (e.g. $120 per meal).

The reporting of transfers of value is considered below as well as setting the standard for other interactions with healthcare professionals such as promotional material, market research, PFPs/starter packs, ghost writing, clinical trials and scientific research, and relationships with organisations.

**Reporting requirements of pharmaceutical companies regarding their interactions with healthcare professionals**

Medicines Australia has made significant changes to the transparency reporting under the Code which are due to commence on 1 October 2015 (a detailed summary is provided in the *Background* section above). Notably, under the new reporting regime in edition 18 of the Code:

- member companies must report transfers of value made to individual healthcare professionals (subject to the healthcare professional’s consent), split up into ‘registration’, ‘travel/accommodation’ and ‘fees’
- food and beverage expenditure will no longer be reported (other than for some third party run events) but, as noted above, is capped at $120 per meal, providing clarity and certainty regarding the scope of hospitality
- event costs [the ACCC understands that this includes event venue hire, transportation costs e.g. transfers, materials provided to attendees, third party costs (such as event organiser) and audio visual costs] at company run events will no longer be reported
- reporting of third party run events is unchanged from edition 17 of the Code (other than that reporting is no longer required if the only cost is food and beverages).

Medicines Australia submits that the interaction between pharmaceutical companies and healthcare professionals is important to the integrity of patient healthcare in Australia and it is essential that the community knows about it and appreciates its contribution.

Medicines Australia also emphasises the importance of transparency, noting in edition 18 that:

> Transparency reporting is a public benefit to provide visibility for consumers of payments and transfers of value to healthcare professionals who are engaged in patient care.

---

54 Medicines Australia submits that around 50 percent of events reported currently involve sponsorship for a third party institution.
Medicines Australia submits that the amendments to transparency reporting in the Code:

- significantly strengthen and expand on the existing public benefits associated with the Code while ensuring that the public benefits associated with the interactions between member companies and healthcare professionals are not affected
- in no way prohibit more stringent and comprehensive requirements being applied by individual companies
- represent the growing community expectation identified by the ACCC in its authorisation of edition 17 of the Code that transfers of value to healthcare professionals be disclosed.

**Interested parties – submissions prior to the draft determination**

MSD, GSK, Pfizer, the AMA and Therapeutic Guidelines support the changes to the Code and/or reauthorisation, particularly the changes relating to transparency reporting:

- MSD and GSK consider that the changes to the Code are a significant shift towards greater transparency by the innovator pharmaceutical industry and are manageable and practical. GSK notes issues such as the autonomy of healthcare professionals, privacy legislation, the importance of offering all healthcare professionals education and resource considerations.
- The AMA submits that the changes to the Code go further than those required by the ACCC in 2012 and represent a realistic and common-sense approach, noting that there is no evidence yet of the positive or negative impact of individual reporting on healthcare systems, healthcare professionals’ decisions or patients.
- GSK submits that transparency will build on public understanding of the importance of educational events. GSK notes that it has been reporting since 2010 and is phasing out payments for speakers/conference attendees and incentives for direct sales representatives.
- Pfizer submits that educational events sponsored by the industry are valuable and that a healthy working relationship between the industry and healthcare professionals is in the best interests of patients.

The RANZCP, the Pharmacy Guild of Australia (the Guild), the Australian Primary Healthcare Nurses Association (APNA), the SHPA, the Australian Society of Anaesthetists (ASA) and the South Australian Medicines Advisory Committee (SAMAC) support the transparency amendments in the Code in principle but suggest some changes. Further:

- the ASA notes the issues around transparency reporting and privacy, optional disclosure and the lack of a centralised database; however it notes that non-member companies have no reporting obligations
• the APNA submits that the manner in which disclosure is managed should not infer bias or unfairly diminish the standing of healthcare professionals.

127. The Pharmaceutical Society of Australia (PSA) submits that the success of the Code should be closely monitored and refined as necessary.

128. A number of interested parties consider that the ACCC should not authorise edition 18 of the Code as it does not adequately achieve transparency:

• The RACGP, Dr Harvey and CHOICE submit that the transparency in edition 18 of the Code is not an incremental improvement and its authorisation would result in public detriment.

• A number of parties suggest that the transparency regime fails to deliver on the key outcomes raised with Medicines Australia by interested parties and the TWG (including the TWG’s principles, such as to give consumers well informed decisions, cover all transfers of value, report individually and utilise a central database) and that to claim broad support is flawed.

• Professor Haines and the CHF submit that transparency of transfers of value to healthcare professionals is critical. Professor Haines submits that relevantly: there is a culture of entitlement amongst doctors; transfers of value affect how studies are designed and reported; key opinion leaders are influential; healthcare professionals are spending vast public money; and consumer safety must be considered.

• Ms Marcus considers that it is critical that regulators support transparency.

ACCC view

129. The ACCC accepts that there are benefits in appropriate reporting under the Code (noting that such reporting may not exist absent the Code). However, the nature of that reporting should be guided by community expectations. The ACCC specifically emphasised this issue when it authorised edition 17 of the Code in 2012:

The ACCC remains of the view that there is merit in providing greater transparency around the sponsorship provided to healthcare professionals by pharmaceutical companies to attend educational events. The ACCC considers that there is growing community expectation that such payments will be disclosed, which is reflected in submissions received by the ACCC and in developments such as the introduction of the US Physician Payment Sunshine Act.

...the ACCC considers that [the] benefits [resulting from reporting measures] may be undermined if the Code departs too widely from community expectations. The ACCC considers that the effectiveness of voluntary codes is enhanced when the standards incorporated are meeting identified

55 The RACGP; CHOICE; the CHF; Cancer Voices; Dr Harvey; Mr Kirwood; Professor Morris; Professor Haines; 25 Individuals.

56 The PSA; the RACGP; the SAMAC; CHOICE; Dr Harvey; Professor Morris; 25 Individuals.

objectives and current community expectations. The ACCC notes that the Code explicitly states that “therapeutic industry codes have as their primary objective the maintenance of the trust and confidence of, and accountability to, all communities with which they engage, the effectiveness of which is assessed through the eyes of the relevant community”.  

...if the Code is not amended in a timely manner to reflect current community expectations, the public benefits from the Code could be undermined. Accordingly, the ACCC expects Medicines Australia to incorporate new provisions into the Code that will facilitate greater disclosure around sponsorship and fees paid to individual doctors prior to lodging any application for reauthorisation. In assessing any future application for authorisation of the Code, the ACCC will consider the extent to which the Code provides for disclosure of sponsorship and fees paid to individual doctors as part of its assessment of public benefits and detriments resulting from the Code. The ACCC also notes that the Tribunal has stated that where the relevant public benefits test under s90 is satisfied, the decision whether to authorise remains discretionary.

130. In the draft determination, the ACCC acknowledged that Medicines Australia has included new individual transparency reporting requirements in edition 18 of the Code. In principle, and insofar as they represent a move to individual reporting of benefits provided by member companies to healthcare professionals, these changes would seem to be significant and represent an improvement over edition 17.

131. However, the ACCC noted concerns raised by interested parties in relation to the following aspects of the new transparency regime:

a. that transfers of value can be made to healthcare professionals, but not reported, where the healthcare professional does not consent to reporting. The ACCC proposed a condition of authorisation in this regard

b. coverage of the regime and in particular, the reporting of food and beverage expenditure and whether to include drug names in reporting

c. accessibility of the data, including the availability of a central reporting system.

132. Each of these issues is addressed in more detail below.

a. Healthcare professionals’ consent

Medicines Australia

133. Under the new reporting regime as currently drafted, individual transfers of value will only be reported if the healthcare professional consents to the disclosure. Where individual transfers of value cannot be reported (for example if a healthcare professional does not consent to the relevant information being published), these amounts must be reported in aggregate by each member company, along with the number of recipients. Member companies must also provide healthcare professionals at least six weeks to review and submit corrections to the information

59 Re Medicines Australia Inc [2007] ACompT 4 at paragraph 122.
prior to publication.\textsuperscript{60} In its supporting submission, Medicines Australia submits that it is inappropriate to make consent to disclosure a condition of receiving the transfer of value as, it says this will negatively impact patients and member companies.

134. In deciding on this approach, Medicines Australia submits that it had regard to matters including the following:

- the application of Australian privacy legislation with respect to reporting a healthcare professional’s personal information
- the purpose for which the information is collected in relation to Australian privacy law
- healthcare professionals retrospectively withdrawing consent to have their personal information published.

135. Medicines Australia sought the advice of the Australian Privacy Commissioner on the above issues on 8 April 2014. The Privacy Commissioner responded on 15 May 2014. With respect to the reporting of personal information relating to transfers of value made to individual healthcare professionals, the Privacy Commissioner advised that such reporting appeared to be disclosure of the information for a secondary purpose. Therefore the information could only be disclosed if an exception set out in Australian Privacy Principle 6 applied:

- the individual consents to disclosure or
- the individual would ‘reasonably expect’ the organisation to disclose the information for the secondary purpose and the secondary purpose is ‘related’ to the primary purpose of collection (for non-sensitive information).

136. The Privacy Commissioner agreed with the view expressed by Medicines Australia that seeking consent would be ‘best practice’. However, the Privacy Commissioner noted that the proposed reporting could also fall within the second exception, and that it appeared the reporting could be considered to be ‘related’ to the primary purpose of collection as required by this exception.

\textit{Interested parties}

137. Pfizer submits that increased transparency delivered by an industry code requires the support of healthcare professionals and peak bodies. Pfizer submits that transparency must be increased by reasonable and workable measures in order to maintain relationships, and there are a number of outstanding issues to be resolved through ongoing discussions.

138. The Department of Health supports requiring companies to report on transfers of value to individual healthcare professionals, pending the consent of the healthcare professional.

\textsuperscript{60} See sections 41.3.1-41.3.3 of the Code.
139. The AMA considers that it is unlikely that healthcare professionals who object to their information being disclosed will continue in such relationships with pharmaceutical companies.

140. A number of interested parties considered that healthcare professionals should not be able to accept transfers of value but choose not to consent to their information being reported, since opting out of disclosure will mean that patients cannot access this information.61

141. For example:

- the CHF, the RACGP, Cancer Voices, CHOICE, the PSA and Dr Harvey submit that the transparency regime is undermined where practitioners have no commitment to ensure transparency and disclosure of these arrangements

- the RACGP, CHOICE and a number of individuals submit that the ability for healthcare professionals to opt out of disclosure defeats the purpose of the TWG proposal and is at odds with the submissions of interested parties more broadly

- the SHPA submits that the total cost for an attendee for an educational event or professional development activity should be advertised to invitees as part of the consent/acceptance process

- Professor Morris considers that Medicines Australia has not substantiated its concerns about the potential impact on public health and the uneven playing field in the industry, and notes the potential public benefits

- Dr Harvey submits that there are sufficient non-industry controlled, independent, medical education opportunities to assist healthcare professionals. Professor Morris and Dr Harvey submit that there are opportunities for Medicines Australia companies to contribute grants to independent non-industry controlled medical education events to assist healthcare professionals with their continuing professional development

- Dr Harvey submits that it is unlikely that imposing the transparency regime on member companies would provide any great advantage to generic companies as generic manufacturers promote direct to pharmacists.

142. In response, Medicines Australia reiterated its previous submissions and, with respect to competition between its members and generic manufacturers, noted that the transparency regime also applies to interactions between member companies and pharmacists (not just doctors). Further, Medicines Australia submitted that at least 35 percent of medicines supplied under the PBS by volume are supplied by non-member companies, such as generic manufacturers, who compete with member companies.

---

61 The RANZCP; the SHPA; the RACGP; CHOICE the CHF; Cancer Voices; Dr McEvoy; Dr Harvey; Professor Haines; Professor Morris; 25 Individuals.
In a submission following the draft determination, the PHAA submits that mandatory disclosure is not a trivial matter given the issue of over-prescribing as a result of the promotion of medicines.

Draft determination

As noted previously, in the draft determination the ACCC proposed to impose a condition to ensure that all relevant transfers of value by member companies to individual healthcare professionals are publicly reported.

Submissions responding to the proposed condition are summarised under \textit{Conditions of authorisation} below (paragraphs 359 to 437).

ACCC view

The ACCC recognises that the introduction of a transparency regime requiring Medicines Australia’s member companies to report on transfers of value provided to healthcare professionals on an individual basis is a significant and important change to the Code. The kinds of transfers subject to such reporting include those that have been identified by interested parties as being of greatest concern or value.

The ACCC notes that individual reporting has the potential to, at least partly, address the principal agent problem (and conflict of interest) by giving patients some transparency over a matter which may influence the objectives of, and treatment provided by, their prescribing healthcare professionals - being the extent to which those professionals have received transfers of value from pharmaceutical companies. Currently, patients have no way of acquiring such information. The ACCC considers that providing broad access to and scrutiny of this information could also assist to maintain community confidence in the transactions between healthcare professionals and member companies.

Being aware of transfers of value received by a particular healthcare professional may alert a patient to a possible influence on their healthcare professional’s prescribing decisions, and enables the patient to explore this further, should they wish to do so. For example, a patient could search for the transfers of value received by their doctor and decide whether to raise this with their doctor, research the matter further or seek a second opinion. Such information could also be highly relevant to a patient’s choice of healthcare professional in the first place.

This information could also be used by fellow healthcare professionals to inform themselves about matters which may be relevant to their understanding of, for example, a key opinion leader in their field. Secondly and relatedly, it would deter member companies from making, and healthcare professionals from accepting, transfers of value which are inappropriate or which may raise conflicts of interest if these transfers are subject to public scrutiny.

In the draft determination, the ACCC noted that in order for the individual transparency regime to be effective, all transfers of value must be reported.

The approach currently adopted in edition 18 means that individual reporting will only occur if a healthcare professional who has received a transfer of value explicitly consents (‘opts in’) to their information being reported individually.
Therefore member companies will be able to continue making transfers of value to healthcare professionals without the transfers being individually reported.

152. As noted in the draft determination, it is difficult to envisage that all healthcare professionals will consent to disclosure. According to Medicines Australia’s recent survey results, over 40 percent of healthcare professionals were unlikely to provide consent.

153. Healthcare professionals’ attitudes may also change once faced with the option to withhold consent, particularly if they are aware that their peers will not be ‘opting in’. If a significant proportion of healthcare professionals do not consent to disclosure then it is hard to see that the transparency regime originally proposed by Medicines Australia offers any improvement over the existing transparency reporting.

154. Even if most (but not all) transfers of value are individually reported, without knowing what has not been reported, it will be difficult to use or rely upon the information that has been reported. For example, it will be difficult (if not impossible) for a patient to understand the significance or relevance of transfers made to a healthcare professional where it is not possible for the patient to ascertain:

- whether that is the full extent of transfers made to that practitioner (given that it is open to a healthcare practitioner to consent to the disclosure of some transfers of value but not others)
- the nature or extent of transfers made to other practitioners.

155. This results in a disclosure regime that cannot be relied upon as a means to disclose all potential conflicts of interest, which fundamentally undermines the transparency objectives of the regime and significantly compromises the potential benefits of an otherwise appropriate regime.

156. The ACCC notes that Medicines Australia considers it is best practice to obtain consent to disclosure in this situation; however, the ACCC has concerns with member companies requiring consent (as discussed at paragraph 376). The ACCC expects that in any event once a universal transparency regime is introduced, an industry-wide expectation of individual reporting of transfers of value will quickly be established.

157. The ACCC acknowledges Medicines Australia’s concerns that withholding transfers of value to some healthcare professionals may negatively affect patient care and the competitiveness of its members. However the ACCC does not think these concerns justify compromising the transparency regime. If member companies are concerned that healthcare professionals may choose not to attend educational events because of the associated transparency reporting, companies can offer events that do not require reporting (for example, where no transfers of value are provided). Further, healthcare professionals who have concerns with individual reporting could rely on their employer to fund or self-fund to attend third party education events, rather than relying on sponsorship by a member company.

158. Relevantly, some healthcare professional industry associations (such as the RACGP, the SHPA and the RANZCP) support the need for individual transparency, which suggests that their members do not share a concern about missing out on educational content.
159. Further, healthcare professionals could take comfort knowing that all transfers of value from member companies to all healthcare professionals will be reported (i.e. a requirement that all transfers of value to healthcare professionals be reported will ensure a ‘level playing field’ between healthcare professionals in their dealings with member companies).

160. The ACCC agrees that any transparency regime should have regard to the requirements of Australian privacy legislation. However, the ACCC does not agree that this necessarily compromises the coverage of the reporting regime. The ACCC considers that, rather than allowing companies to make transfers of value but not report them, the only transfers of value which should be made are those which will be able to be reported. In effect, this means that member companies should only make transfers of value to healthcare professionals where they have taken appropriate steps to ensure that the healthcare professional reasonably expects the disclosure.

161. The ACCC proposed a condition in the draft determination and, taking into account submissions by Medicines Australia and interested parties, has amended that proposed condition to move away from a consent based approach, by precluding member companies from making transfers of value unless they have taken reasonable steps to ensure that the healthcare professional will reasonably expect disclosure.

162. Medicines Australia and its members indicated that they are willing to accept the condition proposed in the ACCC’s draft determination subject to a 12 month delay in its implementation. Given that the new transparency regime is a significant change to the Code, the ACCC has also amended the condition to allow it to come into operation on 1 October 2016.

163. These amendments to the condition, along with submissions on the proposed condition and the ACCC’s assessment, are discussed in more detail under Conditions of authorisation below.

b. Coverage of transparency regime (in particular, the reporting of food and beverage expenditure and whether to include drug names in reporting)

164. Medicines Australia notes that the new transparency model is similar to that introduced in Europe by EFPIA in that recording is by activity rather than amount spent. Medicines Australia submits that like the EFPIA model, the Code:

- sets a maximum for the transfers of value associated with meals and beverages. This ensures that any hospitality is appropriate and reduces the reporting burden for member companies
- captures specific transfers of value
- requires reporting on a regular basis.

165. As noted above, the EFPIA model also requires individual disclosure (subject to ‘legal reasons’, such as data protection and other laws, in which case amounts shall be disclosed in aggregate).
166. Medicines Australia submits that benefits of this model include:

- capturing significant transfers of value while avoiding low level hospitality
- capturing a range of interactions between member companies and healthcare professionals
- avoiding the complexity and administrative burden of capturing low level hospitality at the individual healthcare professional level.

167. Medicines Australia submits that the model meets the needs of Australian consumers. Medicines Australia gauged from the consumer workshops and other feedback that there was general support for an activity based approach on the grounds that the type of activity leading to the transfer of value (rather than the dollar value) might be a more reliable predictor of influence, and would be the simplest, quickest and most cost effective way to get a model up and running.

Interested parties

168. The AMA and Pfizer support following the EFPIA model for the reasons noted by Medicines Australia.

169. Dr Smith agrees that reporting of small payments will only serve to obscure the large payments.

170. The Guild supports the changes to reporting of hospitality.

171. However, other interested parties suggested a number of areas where the transparency reporting should be expanded:

- The Department of Health submits that any payments relating to Patient Support Programs should be included.
- The SHPA, the RACGP and Dr McEvoy are concerned that hospitality costs and venue costs will no longer be reported. As such, healthcare professionals could attend a function that is no longer required to be reported.
- The RANZCP, the ASA and Dr Smith submit that the funding of health professionals for the purpose of pharmaceutical research and development should be reported. Following the draft determination, Dr Smith and Mr Kirwood reiterated this view. The SHPA supports including clinical trials in reporting. Dr Harvey submits that it is appropriate that research be excluded in the interests of minimising the reporting burden.
- Cancer Voices submits that reporting should include the drug name.
- The RACGP considers company representative visits, for example for hospitality costing $25 or more, or $100 annually (i.e. accumulation of all hospitality above $10), should be reported.
- Ms Marcus considers that all acceptances of gifts, in kind or otherwise, should be recorded.
• Cancer Voices\textsuperscript{62} submits that sponsorship or gifts given to, for example, small practices should be reported.

• The SHPA and the SAMAC consider that PFPs and starter packs should be included in the new individual transparency reporting.

• Professor Lexchin submits that transparency reporting should extend to product samples, trial loans of medical devices and educational materials that are intended to be used by or with patients.

• The SHPA submits that the Code should include a new section on the relationship between pharmaceutical companies and healthcare/employer organisations which mirrors the section relating to the relationship with individual healthcare professionals.

172. Some interested parties also suggest introducing reporting thresholds:

• The RACGP suggests that there should be cumulative thresholds for reporting (e.g. in respect of hospitality). Further the RACGP considers that the $120 per meal limit for hospitality is too high.

• The APNA suggests aggregate reporting of transfers of value and individual reporting only in relation to healthcare professionals who depart from the mean or median for the profession.

• The Guild suggests encouraging healthcare professionals to report but requiring mandatory reporting for amounts above a threshold (and aggregate reporting for smaller amounts). If there is a high proportion of individuals not consenting then there may be a case to make disclosure mandatory in future editions of the Code.

• In a submission following the draft determination, the SHPA submits that any transfer above $25 (or $1000 for businesses), or if there were more than 10 interactions in 12 months, should be reported.

173. In its response to third party submissions, Medicines Australia reiterated its previous submissions and also submits that:

• most costs attributable to an individual will continue to be reported, other than meals and beverages

• the TWG did not reach consensus on a model. Following the release of the TWG’s findings, EFPIA published an activities based code. Medicines Australia submits that it raised the EFPIA code as an alternative with its Code Review Panel and in consumer workshops in October 2013 (and in further consultation and in seeking submissions in April/May 2014). Medicines Australia considers that it consulted widely on the activity based model and made the TWG paper readily available

• visits from pharmaceutical sales representatives are not reportable under either edition 17 or edition 18 of the Code where those visits are not educational events

\textsuperscript{62} In submissions both before and after the draft determination.
• although costs of running educational events are not reportable, member companies cannot circumvent the transparency principles. In particular, there are provisions in the Code which ensure that educational events are appropriate having regard to content, venue and food and beverages (entertainment continues to be banned). Also, the content of third party meetings is to be determined independently of sponsorship by a member company

• clinical research should not be included in the transparency reporting as: this funding is generally provided to institutions such as hospitals rather than individual healthcare professionals (who are usually paid a salary, for example by the public hospital system); funding payments generally cover all of the costs relating to the conduct of the clinical trial (not just the researchers’ remuneration); and often multiple healthcare professionals will work on a clinical study over time

• relationships with medical practices (or healthcare/employer organisations) are adequately addressed in the Code. For example: requirements for financial support for medical practice activities; reporting of transfers to an individual that are ultimately made to another entity; reporting of sponsorship of independent events; and a company may only temporarily loan a piece of equipment to a medical practice

• the value associated with starter packs/PFPs should not be reportable with respect to individual healthcare professionals under the transparency reporting as these items go directly to the patient.\(^{63}\)

174. Following the draft determination, the CHF submits that the industry should take the necessary administrative, logistical and technological steps to prepare for further disclosure requirements (e.g. new categories of reporting) in the future.

**Reporting of food and beverage expenditure**

175. As noted above, prior to the draft determination a number of interested parties raised concerns regarding the loss of food and beverage reporting in Edition 18 of the Code.

176. In the draft determination, the ACCC identified that there may be merit in including some form of continued reporting of food and beverages provided by member companies (in addition to or instead of a monetary cap on hospitality). Relevantly, hospitality is a direct transfer of value to individual healthcare professionals. The ACCC posed several possible options to address this issue.

177. Medicines Australia submits that all of the food and beverage reporting options posed by the ACCC in the draft determination increase the complexity and/or administrative burden and cost of the reporting regime, in circumstances where its members are moving to a new regime of individually reporting all relevant transactions. It says that companies will not have the resources to do this as compliance staff will be redeployed to the new transparency reporting and it would also necessitate companies running two reporting systems. The AMA submits that

\(^{63}\) See the following sections of the Code: 41.3.1; 9.5.1; 9.10; 9.12; 9.11.4.
these costs would be borne by the healthcare system. Medicines Australia also submits that the $120 cap should not be reduced.

178. Professor Morris, Sanofi, Novo Nordisk, Celgene and Pfizer agree that ongoing food and beverage reporting is unnecessary.

179. Medicines Australia estimates that, based on a review of data in the current educational event reports, the following will continue to be reported under edition 18 of the Code:

a. 68 percent of the total expenditure on healthcare professionals currently reported by member companies
b. 96 percent of sponsorship to attend an educational event
c. 98 percent of consulting services costs
d. 84 percent of advisory board costs
e. 71 percent of total function costs for third party events.

180. Medicines Australia submits that around 40 percent of company organised educational events are comprised of food and beverage costs only and will no longer be reportable; however, this represents approximately 13 percent of total expenditure of member companies on functions in a given month.

181. Medicines Australia further submits that it is not appropriate for the ACCC to impose such a condition because: the Code already results in significant public benefits; it would put Medicines Australia’s members at a competitive disadvantage; and aggregate reporting will provide little benefit to the public as trends may be due to other changes in the industry.

182. In further submissions, the RACGP and the CHF support individual reporting of meals above a threshold amount. The SHPA and the PHAA also support hospitality reporting. The PHAA considers that company hospitality results in over-prescribing and significant cost for the PBS. The RACGP is also concerned that many educational events will no longer be reported.

183. Associate Professor Richard O’Brien (Clinical Dean of Medicine, Austin Clinical School, University of Melbourne) submits that financial disclosure rules should be consistent with those of our federal politicians and that no caps should apply.

184. In February 2015, the ACCC consulted with Medicines Australia and interested parties on five revised proposed conditions of authorisation (February consultation). The ACCC did not include any proposed condition that would require any ongoing reporting of food and beverage expenditure, on the basis that:

• food and beverage costs are secondary to the larger and more direct transfers of value
• the individual transparency model is designed to focus on these more direct transfers of value

64 Costs that will not be reported include food and beverage, venue/AV hire, transportation (e.g. transfer costs), materials provided to attendees etc, third party costs such as event organiser.
• the $120 cap on meals introduced in edition 18 will go some way in ensuring that expenditure on food and beverages is not inappropriate

• the administrative burden of reporting food and beverage expenditure, in addition to the new individual transparency regime, would be significant.

185. However, the ACCC did note its concern to ensure that all relevant required expenditures are reported and that such expenditures are not categorised incorrectly as food and beverage expenditure (and therefore not reported under the new regime). The ACCC noted that if food and beverage expenditure was to increase significantly upon cessation of the existing transparency reporting, it may suggest some expenditure is not being categorised correctly. The ACCC therefore proposed that Medicines Australia, when seeking any reauthorisation, provide data on expenditure trends for food and beverage during the period of this authorisation. If the data indicated that there had been an increase in this expenditure, the ACCC suggested it may reconsider its position in relation to food and beverage reporting.

186. In response, Medicines Australia submits that providing trend data would essentially require member companies to continue to record the hospitality reporting data and any such hospitality condition is not necessary or appropriate. Further:

• member companies have an exemplary record of accurately reporting event expenditure

• member companies have comprehensive and enforced compliance policies and systems that have been enhanced over the past five years. This will include strictly enforcing the $120 per meal cap

• the Code is clear about the expenses that must be reported

• there is no evidence member companies are increasing this expenditure

• maintaining reporting is an undue and wasteful regulatory burden.

187. Dr Smith, Professor Del Mar and Dr Purssey are comfortable with the removal of food and beverage reporting (Dr Harvey ultimately agreed with this view).

**Drug name in transparency reporting**

188. As noted, prior to the draft determination Cancer Voices submitted that the transparency reporting should include the relevant drug name.

189. In the draft determination, the ACCC sought submissions on this issue.

190. Medicines Australia submits that it is not appropriate to name specific medicines in the transparency reports. Medicines Australia submits that: it would be difficult to identify a particular medicine for each transfer; it may constitute promoting medicines to the general public; and it will likely increase the complexity and cost of reporting. Sanofi, Novo Nordisk, Celgene and MSD support this view. Pfizer maintains that no other conditions are necessary (including with respect to drug name). Dr Purssey and Dr Harvey also ultimately supported not requiring drug name reporting.
191. Cancer Voices, the CHF and the PHAA consider it is appropriate to name specific medicines in the transparency reports.

192. The February consultation did not include a requirement to report drug names. However the ACCC flagged that Medicines Australia should, prior to any application for reauthorisation, take steps to prepare for the possible inclusion of drug names in the reporting.

**ACCC view on coverage of the transparency regime**

193. The ACCC notes the submissions of interested parties that transparency reporting should be expanded to include various other transfers of value. The ACCC has taken the submissions of interested parties to be mainly in relation to company-run events (as opposed to sponsorship for a third party institution).

194. The ACCC has decided not to require Medicines Australia and its members to continue to report food and beverage expenditure for the reasons noted at paragraph 184. However if the ACCC becomes aware that the removal of the requirement to report expenditure on food and beverages has led to significant (and unreasonable) increases in food and beverage expenditure, it may reconsider the need for reporting of this expenditure.

195. The ACCC also encourages members of the public or others to advise Medicines Australia or the ACCC if they become aware that member companies are breaching the $120 meal cap or have other concerns about food and beverage expenditure following the cessation of reporting.

196. The ACCC notes that there is likely to be utility from reporting the name of the relevant medicine in the individual reporting, if applicable. However, the ACCC acknowledges that reporting the particular drug name may increase the complexity and cost of reporting. The ACCC has decided not to require a condition at this time but expects Medicines Australia, during the period of this authorisation, to undertake a detailed investigation into the reporting of the name of any specific drugs associated with particular transfers of value, as part of the reports on those transfers of value. The ACCC suggests that Medicines Australia look to the approach taken in other jurisdictions where such information is reported.

197. The ACCC is also not proposing to require Medicines Australia to report on the remaining transfers of value raised by interested parties, noting that:

- although venue costs could be significant, they should not be directly attributable to individual healthcare professionals and as such are not captured by the individual disclosure regime. The ACCC also accepts that these costs are less likely to influence an individual healthcare professional’s decisions relative to more direct transfers. The ACCC acknowledges however that this represents a loss of reporting from edition 17

- there are other mechanisms to report on sponsorship of research and development by pharmaceutical companies (such as clinical trials registries). In light of these other mechanisms, the ACCC does not consider that it is a priority to include research and development in Medicines Australia’s reporting at this time
• transfers of value not related to prescription pharmaceuticals are not covered by Medicines Australia’s Code more generally and thus are not reportable

• existing clauses of the Code are adequate with regards to interactions between member companies and practices/other organisations. Also such transfers are not received by an individual healthcare professional

• payments with regard to Patient Support Programs are not currently reported in the transparency reporting.

198. While the ACCC accepts that it is appropriate for edition 18 to focus on the transfers of value of most concern, the ACCC expects that Medicines Australia will expand the reporting requirements over time as appropriate. This should include reviewing the inclusion of the abovementioned transfers of value identified by interested parties.

c. Accessibility of reporting data

199. The RANZCP, the PSA, CHOICE and Cancer Voices submit that there should be a centralised and easily accessible database. Dr McEvoy agrees that the transparency data should be presented in a searchable database (such as Microsoft Excel).

200. In submissions before and after the draft determination, the RANZCP submits that reports should be submitted by member companies to an independent body, rather than to Medicines Australia. Following the draft determination, the SHPA submits that an independent body should manage the reports and create unique identifiers for each healthcare professional.

201. The SAMAC submits that the new reporting should be implemented sooner than October 2015. Further, the reporting tables should specify whether amounts include GST.

202. Cancer Voices submits that the current proposal sees delays of up to 10 months between receipt of the transfer of value by the healthcare professional and notification.

203. Cancer Voices and the SHPA suggest that member companies should make the transparency reports available for between five and seven years, instead of making the information publicly available for two years.

204. As noted previously, Medicines Australia submits that it and its member companies are actively investigating the establishment of a central platform for future disclosure. Medicines Australia submits that there are several outstanding issues to address in order to establish a central platform:

• A unique identifier is necessary in a central database to ensure all member companies are able to report consistently and thus enable the data to be consolidated.

• If a unique identifier can be used, a process needs to be formulated in order to ensure the identifier and associated fields (name and primary practice address) can then be matched with company data.
• If a unique identifier cannot be used, other options include using a third party provider to record the data of all member companies, or using an agreed naming convention.

• Transparency reporting requirements would only be finalised once the Code receives ACCC authorisation.

• A centralised database will need to be scoped, designed and built. Some of the issues that need to be addressed include: who will own the database and the information within it; who will fund the database; who will build the database; who will maintain the database; who will fund the operation of the database; how will privacy requirements be met by the party that is responsible for the database.

• Given the likely cost of establishing and maintaining such as database, it is important to ensure the database is designed to reflect the expectations of potential users.

• Member companies will need to revise their internal systems, interfaces and processes in order to collect and maintain the data in the form required for that database.

205. Following the draft determination, the Australian Privacy Commissioner provided a submission noting that the storage of personal information in a centralised database poses potential privacy issues, including due to the aggregation of personal information. The Commissioner recommends that Medicines Australia conduct a Privacy Impact Assessment (PIA). In a further submission, the Privacy Commissioner submits that a PIA should be conducted before any elements of the database are mandated.

206. Medicines Australia therefore submits that further requirements include:

• conducting a PIA and ensuring member companies can comply with privacy legislation

• technical issues associated with establishing a database.

207. Medicines Australia submits that other reporting regimes internationally, such as the EFPIA model, do not require reporting on a centralised database in all cases. Medicines Australia notes the difficulties experienced in the USA in implementing reporting under the Sunshine Act which it considers demonstrates logistical, legal and technological challenges.

208. At the pre-decision conference, Medicines Australia and the AMA indicated that it was too early to commit absolutely to a centralised database, or even a specific timetable, noting that there are a number of issues to resolve. Medicines Australia referred to issues including the Privacy Commissioner’s concerns and the inability to use the Australian Health Practitioner Regulation Agency (AHPRA) identifier. Medicines Australia noted that reporting under the Sunshine Act had been delayed by inaccuracies in about 25 percent of the data reported.

209. However, Medicines Australia submits that the issues identified are not insurmountable. It submits that it will establish a working group and liaise with members in the first half of 2015. Medicines Australia considers it will take at least
two to three years to investigate and establish a database while avoiding implementation issues.

210. Following the draft determination, Pfizer supports focusing efforts on the centralised database rather than on imposing other conditions. The RACGP, the PHAA, the CHF and the RANZCP consider that a centralised database is very valuable. Some of these parties accept that there are issues to be resolved but the database should not be significantly delayed. The PHAA requests that Medicines Australia be required to keep interested parties informed of progress. The PHAA also submits that the database should be funded by the pharmaceutical industry from fines received through breaches of the Code or from industry profits.

211. Following the draft determination, Professor Morris and the PHAA suggest requiring Medicines Australia to ask member companies to immediately set up their own publicly accessible databases, prior to implementing a centralised database before October 2017.

212. Prior to the draft determination, Medicines Australia submitted that publishing two years of reporting is appropriate so as not to require member companies to facilitate ongoing access to multiple years’ worth of data (at least until a centralised database is introduced). At the pre-decision conference, Medicines Australia queried the utility or need for the information to exist beyond two years and notes that the data relates to personal information.

213. Medicines Australia submits that since November 2012, published transparency reports are character readable. In addition, the transparency reports that will be published under the new transparency regime proposed in edition 18 of the Code will also be published in character readable PDF format.

214. In a submission following the draft determination, Professor Morris and the PHAA submit that prior to the introduction of a centralised database, member companies should provide PDF reports published on Medicines Australia’s website.

ACCC view

215. The ACCC sees a number of benefits arising from the universal reporting of relevant transfers of value to healthcare professionals, including those set out in paragraphs 147, 148 and 149 above.

216. However, the ACCC considers that the scope of the benefits flowing from such universal reporting depends upon the extent to which the information reported is available to, and accessible by, consumers, healthcare professionals and other relevant persons in a practical and meaningful way.

217. The ACCC sees the benefits flowing from consumers being able to access the raw data directly to undertake their own research. The ACCC also sees benefits being realised by the reported information being made available to consumers via communications by third parties, such as healthcare professionals, consumer and healthcare professional bodies, researchers, academics and the media.65 Such communications may be more useful to many consumers than if the consumers were to try to access and make sense of the raw data themselves. In addition, such

---

65 Of course, to the extent that the third parties are subject to Australian privacy legislation, any such use of the data will need to comply with that legislation.
communications may increase consumer awareness of the availability of the reported information, leading them to seek to access it themselves.

218. Data posted on a single, central, searchable site will make it easier for individual consumers to directly access data. It will also facilitate analysis and communication of the data by the third parties referred to above, for the benefit of consumers. Such analysis and communication will assist consumers to become aware of the data and to better understand it.

219. In contrast, data included in separate reports across the individual websites of Medicines Australia's member companies would require knowledge of which company's records are likely to be relevant or a review of all data in order to obtain relevant information. It would also raise difficulties for relevant third parties in analysing and communicating that information to consumers.

220. The ACCC notes that the Tribunal considered that transparency imposes its own constraint on payments made by member companies to healthcare professionals and those companies will have to be in a position to explain these payments in public. The ACCC considers that this has broad benefits, such as increased confidence in the pharmaceutical industry and its interactions with healthcare professionals.

221. The ACCC considers the reporting requirements in the Code (in particular, the HCP Aggregate Transfer of Value Report and the Sponsorship of Third Party Educational Meetings and Symposia report) provide transparency around the provision of transfers of value to healthcare professionals (and other parties) and serves as a disincentive for inappropriate behaviour. The ACCC notes that this would be further strengthened through the provision of data in a single place, via a central reporting system.

222. The ACCC notes the practical implementation issues identified by Medicines Australia and that Medicines Australia is actively investigating establishment of a central platform for reporting. The ACCC strongly encourages Medicines Australia to dedicate appropriate resources to developing a central reporting system and implement it as soon as possible.

223. In the revised proposed conditions of authorisation released following the draft determination, the ACCC proposed a condition requiring Medicines Australia to make reasonable endeavours to implement a central reporting system and to provide six monthly updates on its progress. The ACCC also proposed requiring that, prior to a centralised database being introduced, member companies report in Excel format or similar. Further, the ACCC proposed requiring that three years of data remain published, rather than two.

224. The ACCC understands that the obligation upon member companies to publish reports on relevant transfers of value to healthcare professionals on their websites in section 41.3 of the Code will continue to apply throughout the period of this authorisation (and regardless of Medicines Australia's progress in respect of implementing the central reporting system).

225. The ACCC has decided to impose these conditions, subject to some modification. A summary of the submissions received and the ACCC's approach is provided under Conditions of authorisation below (paragraphs 359 to 437).

Having discussed the reporting of transfers of value to healthcare professionals, the following sections deal with the standard for other interactions with healthcare professionals such as promotional material, market research, PFPs/starter packs, ghost writing, clinical trials and scientific research, and relationships with organisations.

**Promotional material directed at healthcare professionals**

Section 2 of the Code regulates the provision of promotional material to healthcare professionals. Medicines Australia submits two amendments have been made to this section to increase existing public benefits, namely:

- text that is given prominence in printed forms of promotional materials, such as PBS information, qualifying statements and referring the prescriber to review the Product Information, should now be similarly prominent by text size and location in electronic and audio-visual media, and new media
- as above, for e-journals and e-newsletters.  

The Department of Health suggests that provisions be expanded to:

- reflect a commitment to increasing the information publicly available on new medicines considered by the Pharmaceutical Benefits Advisory Committee (PBAC) including making public the evidence used by the PBAC in considering applications and the reasons for recommendations on use and access
- remind companies that it is an offence under subsection 22(5) of the TG Act to advertise a therapeutic good for indications other than those entered in the ARTG for that good and that practitioners are required to comply with codes of professional conduct as issued by their registration boards
- clearly define and delineate the difference between ‘educational material’ and ‘promotional material’.

Medicines Australia notes that it will include references to the TG Act and the codes of conduct published by healthcare professional bodies (although Medicines Australia does not regulate the conduct of healthcare professionals) in the updated Code Guidelines. Medicines Australia is participating in discussions with the Department of Health on how to improve the transparency of the PBAC processes, and under the Code member companies must provide copies of substantiating evidence for a claim to another party on request.

**ACCC view**

The ACCC recognises that Medicines Australia has made incremental improvements in section 2 of the Code and that there is a general public benefit in those provisions of the Code which regulate promotional material. The ACCC notes
the submissions of the Department of Health and Medicines Australia’s response but is not proposing to address the Department of Health’s issues in the current authorisation process.

Market research with healthcare professionals

231. Section 12 of the Code has been extended to ensure that market research is not used as a means to promote an unapproved product or unapproved indication. Fees paid in relation to market research continue to be reportable where the healthcare professional providing information is known to the member company and will be included in the new transparency reporting.

232. The Department of Health suggests that Medicines Australia could expand the post-market surveillance section of the Code to connect post-market surveillance activities undertaken by companies with the post-market programs conducted by both the TGA as regulators and the PBAC.

233. The Department of Health also notes that there is no statement outlining any expectation of compliance with the National Statement on Ethical Conduct in Human Research (National Statement).

234. Medicines Australia does not consider that it is possible for the Code to refer to every statement or guideline which governs the prescription medicines industry (the Department of Health has made this suggestion in relation to a number of sections of the Code).

ACCC view

235. The ACCC notes the Department of Health’s suggestion regarding post-market surveillance activities. The ACCC considers that these issues are best addressed between Medicines Australia and the Department of Health directly, and is not proposing to address these matters in the current authorisation process.

Product Familiarisation Programs and starter packs

236. Medicines Australia defines a PFP as a program run by a pharmaceutical company with the aim of allowing the medical profession to evaluate and become familiar with the product following TGA registration and/or approval of new indications. Healthcare professionals enrol patients in a PFP who are then supplied with the product for a fixed period.
237. Section 7 of the Code regulates how product starter packs can be distributed and has been amended such that:

- healthcare professionals, but not their receptionist, must sign a request for starter packs. Further, companies must keep all records of the request, supply, return and disposal of starter packs for at least two years

- a member company must allow sufficient space on the primary label for a dispensing label and supply pre-printed adhesive labels that comply with the Standard for the Uniform Scheduling of Medicines and Poisons.\(^{68}\)

238. Section 8 of the Code regulates the use of PFPs by member companies to ensure PFPs continue to be conducted in a rigorous manner and are appropriately regulated and are facilitated in a practical manner for patients, healthcare professionals and member companies. Section 8 has been amended to:

- introduce additional requirements in relation to patient information documents supplied in association with PFPs. In particular, a patient must sign their consent that the PFP will be provided for a fixed period after which it may only be available under a private script

- include that only starter packs that comply with the requirements of section 7 of the Code may be supplied free of charge to prescribers for these programs for use by a patient (however trade packs may now be supplied free of charge for a PFP)

- allow for aggregated data on a healthcare professional’s experience with the PFP product to be collected without a formal protocol. A PFP may also enable the collection of individual patient data under a formal protocol

- include a new section which provides that on request companies must promptly accept the return of and appropriately dispose of their products supplied under a PFP.\(^{69}\)

**Interested parties**

239. The CHF supports informed consent protocols around PFPs such as a signed section for a patient to provide consent.

240. The Department of Health supports requiring companies to supply labels to healthcare professionals with a product starter pack. The Department of Health suggests a number of further changes, including:

- the Code should include a clearer differentiation between starter packs and product samples

- strengthening the requirement for companies to advise patients that the future availability of a PFP medicine at a concessional rate is not

\(^{68}\) See in particular section 7.7 and section 7.8 of the Code.

\(^{69}\) See in particular the following sections of the Code: section 8.11; section 8.7; section 8.9; section 8.4.
guaranteed, and to reiterate this advice at all stages of the distribution/supply chain

- companies should have a protocol for systematic collection and analysis of patient safety data and the findings and analysis of data arising from a PFP should be made available on the company’s website and to the TGA/Drug Utilisation Sub-Committee/PBAC
- further clarification of when the rationale for a PFP will be made available
- a reference to the National Statement.

241. The PSA and the SAMAC submit that the use of starter packs should be discouraged. Mr Carney, Ms Marcus and the SAMAC have concerns with the use of PFPs, submitting that PFPs:

- should only be used when a drug has been considered by the PBAC and added to the PBS
- should guarantee continuity of supply until the patient is able to access the product through an alternative funding mechanism.

242. Medicines Australia submits that the Code already appropriately regulates the use of starter packs/PFPs (noting that without the Code there would be no regulation of PFPs/starter packs). However, Medicines Australia submits it will provide clearer differentiation between product starter packs and product samples in the Code Guidelines for edition 18.

243. Medicines Australia notes edition 18 incorporates several amendments which go toward addressing the Department of Health’s concerns, for example with respect to the information provided to a patient about a PFP, requests for the rationale of a PFP and reporting adverse drug reactions under the TG Act.

ACCC view

244. The ACCC notes the concerns of interested parties about the impacts of PFPs and starter packs. However, the ACCC accepts that PFPs and starter packs can benefit healthcare providers and patients if used appropriately. The ACCC accepts that there are some public benefits arising from the regulation of PFPs/starter packs under the Code.

245. Interested parties raised similar concerns with respect to edition 17 of the Code. At that time, the ACCC encouraged Medicines Australia to assess the use of PFPs during the next review of the provisions of the Code. The ACCC notes that Medicines Australia has made several improvements to the relevant section of the Code, and encourages Medicines Australia to continue to include PFPs (and starter packs) in future reviews of the Code.

Ghost writing

246. Section 11 of the Code has been amended to define a ghost writer as a writer who is not acknowledged in a publication, as distinct from professional medical writers who are acknowledged (ghost writing is not acceptable under the Code).
The Department of Health submits that to ensure transparency of authorship or contribution to a publication, companies should follow the principles described in, or the Code should make reference to, various position papers, statements and codes.\footnote{These include:}

Dr Mintzes submits that the Code has a ‘weak standard’ to prevent ghost writing and that the Code only addresses clinical trial publications.

In response, Medicines Australia reiterates that ghost writing (as defined above) is unacceptable under the Code and is not limited to clinical trial publications.

\textit{ACCC view}

The ACCC considers that Medicines Australia’s amendments to section 11 of the Code represent an improvement on edition 17 and a public benefit.

\textbf{Clinical trials and scientific research}

The Department of Health submits that with respect to research:

- the introduction and the Research section of the Code should include references to relevant codes and position papers\footnote{In particular: \textit{National Statement on Ethical Conduct in Human Research}, 2007; IFPMA/EFPIA/Pharmaceutical Research and Manufacturers of America/Japan Pharmaceutical Manufacturers Association \textit{Joint Position on the Disclosure of Clinical Trial Information via Clinical Trial Registries and Databases} (2009); and \textit{Joint Position on the Publication of Clinical Trial Results in the Scientific Literature} (2010) in relation to disclosure and publication.}
  
- the Code could encourage all researchers to ensure that an open access version of their publication is made available.

Medicines Australia submits that as the Code does not apply to researchers or research institutions the Code is not the appropriate vehicle to encourage researchers to publish results of their research. Medicines Australia submits that as the Code does not regulate clinical trials (the conduct of clinical trials is regulated by legislation) the Code is not the appropriate vehicle to deal with the conduct of clinical trials.

\textit{ACCC view}

The ACCC notes Medicines Australia’s response to the Department of Health’s concerns and considers that these issues are best dealt with between the parties, and is not proposing to address these matters in the current authorisation process.
ii. Relationships between pharmaceutical companies and health consumer organisations and patients

254. The Code regulates member companies’ relationship with Health Consumer Organisations (HCOs) and patients, including sections in the Code regarding: relationships with HCOs; sponsorship of patients or representatives of HCOs to attend events; trade displays at conferences; Patient Support Programs; and member company access to dispensary data.

255. In this and/or previous authorisation processes interested parties have raised particular concerns regarding relationships with HCOs and the use of Patient Support Programs, which are discussed further below.

Health consumer organisations

256. Edition 18 of the Code continues to require member companies to provide Medicines Australia with information on the support provided to HCOs. The report must list the HCOs that receive support from the member and must also include: a description of the nature of the support; and the monetary value of financial support and of invoiced costs, or a description of non-monetary costs.

257. Medicines Australia does, and will continue to, make the reports publicly available on its website within two months of receiving the reports. Member companies must inform the HCOs that sponsorship will be publicly disclosed.

ACCC view

258. The ACCC considers that maintaining the existing reporting requirements ensures ongoing transparency. The ACCC considers this constitutes a public benefit.

Patient Support Programs

259. Medicines Australia submits that section 17 of the Code regulates Patient Support Programs and already ensures that patients receive direct disclosure about any payments made to healthcare professionals in association with such programs. Edition 18 of the Code has been amended to include an explicit requirement that suspected Adverse Drug Reactions noted during monitoring of a Patient Support Program must be reported to the TGA.

260. The Department of Health suggests further amendments to section 17 of the Code, namely to:

- clarify that ‘the healthcare and wellbeing of patients must be the only objective of a Patient Support Program’
- better clarify what is encompassed by Patient Support Programs
- require that ‘all information provided to patients must comply with Sections 13 and 17 of this code’
• specify that the Consumer Medicine Information provided to the patient must be the same version as published on the TGA website to ensure it is not promotional

• include a statement outlining an expectation of compliance with the National Statement.

261. The CHF suggests that the Code should include a clause prohibiting package inserts to promote Patient Support Programs, as package inserts should only contain the most important information needed by consumers to support Quality Use of Medicines.

262. Medicines Australia notes that the introduction to the Code has been drafted to adopt the ‘Guiding Principles’ from the International Federation of Pharmaceutical Manufacturers & Associations’ (IFPMAs) Code of Practice (2012). Medicines Australia submits the IFPMA Code sets out principles for the ethical standards expected of the medicines industry globally.

263. Further, Medicines Australia submits it has adopted several of the Department of Health’s suggested amendments. For example, section 17 of edition 18 of the Code now provides that the ‘health and wellbeing of patients must be the objective of a Patient Support Program’, rather than the ‘primary objective’ as previously drafted. However, Medicines Australia submits it will consider including further detail on clarifying what is encompassed by Patient Support Programs in the Code Guidelines.

264. Medicines Australia also notes that Patient Support Programs must not be promotional and have been accepted by the TGA as a legitimate activity. Medicines Australia submits other sections of the Code are also relevant and ensure that promotion to the general public does not occur. Medicines Australia considers these sections of the Code appropriately regulate the provision of such programs and that further amendment to the Code is not required.

ACCC view

265. The ACCC previously noted that the Code recognises that Patient Support Programs may assist patients to understand their condition and better manage their health, or encourage adherence to the medicines they have been prescribed.

266. The ACCC accepts that the Code regulates the way in which Medicines Australia members operate Patient Support Programs, and encourages compliance with the legislative prohibitions on advertising to the public. The ACCC accepts that these constitute public benefits.

267. However, the ACCC considers that it is important that Medicines Australia members ensure that the boundaries between activities that aim to inform consumers and direct-to-consumer advertising do not become blurred. The ACCC acknowledges that Medicines Australia has made changes to section 17 of the Code and encourages Medicines Australia to continue to review this section of the Code as appropriate, perhaps in any future review of the Code.

---

72 For example section 13 of the Code.
iii. Protection of public from inappropriate advertising

268. Medicines Australia submits that the Code contains an overarching general principle that pharmaceutical companies cannot promote prescription medicines to the general public.

269. Medicines Australia considers that section 13 of the Code as amended in edition 18 encourages compliance with the existing legislative provisions prohibiting the advertising of prescription medicines to the public, and ensures that the prohibitions and guidelines about inappropriate advertising in the section are clear and definitive. Medicines Australia submits that this strengthens the public benefits associated with these provisions of the Code.

270. Amendments to section 13 of the Code include:73

- requiring that all information provided by member companies to members of the general public must be current, accurate, balanced and not mislead, and statistics must be referenced
- requiring that educational material that can be accessed by the general public must not (rather than should not) focus on a particular product. Also, the linking of a disease education activity/website to a specific prescription product would breach the Code and therapeutic goods legislation
- introducing a new definition of patient aids
- clarifying what constitutes market research. Patients who have been prescribed a particular prescription medicine can now be asked market research questions as long this is not promotional.

271. The ACCC notes that the Department of Health has suggested a number of further amendments, in particular the Code should:

- remind companies that it is an offence under the TG Act to advertise to the public a therapeutic good that contains a substance included in the relevant schedules of the Poisons Standard
- include provisions that demonstrate Medicines Australia’s commitment to open and unambiguous data and analysis, particularly relating to PBS expenditure, by crediting all sources
- specifying that branding of patient aids should not be product branded, as this may breach the TG Act
- market research may constitute an activity for which the requirements of the National Statement apply
- incorporate the ‘reasonable person’ test in its ‘Advertisement’ definition to be fully consistent with the TG Act.

---

73 See in particular: section 13.1; sections 13.6, 13.8, 13.9; section 13.7; section 13.11.
272. In response, Medicines Australia reiterates that edition 18 of the Code requires that all public statements must be referenced to their source. In relation to patient aids, the Code provides that any item (including patient aids) that is used outside the home (i.e. where a member of the public could see the item) may not be product branded.

ACCC view

273. The ACCC has previously accepted that the Code encourages compliance with existing legislative prohibitions on advertising to the public and results in a public benefit. As noted by the Tribunal there are limits to legislation and the Code has a potentially wider coverage. Further there are costs associated with the investigations and judicial processes involved in the enforcement of statutory regulation.

274. The ACCC considers that the provisions in edition 18 of the Code that protect the public from inappropriate advertising continue to give rise to a public benefit.

275. The ACCC notes that Medicines Australia has already addressed some of the suggestions from the Department of Health and the ACCC considers that any further discussions should be conducted between Medicines Australia and the Department of Health directly.

iv. Standards for medical and promotional claims

276. Medicines Australia notes that the Code contains provisions that:

- require all promotional claims to be consistent with Product Information approved by the TGA
- specify the content and layout of minimum Product Information and the circumstances in which each must be used
- prohibit the use of abstracts and poster presentations as primary evidence to support a promotional claim and specifies the circumstances in which such information may be used as secondary evidence.

277. Three amendments have been made to section 1 of the Code relating to the nature and availability of information and claims made regarding member companies’ products:

- with regard to ensuring medical claims are balanced, ‘companies must ensure that adequate safety information is included in relation to efficacy or other promotional claims’
- with respect to false or misleading claims, data previously valid but made obsolete or false must (rather than should) not be cited

---

74 Re Medicines Australia Inc [2007] ACompT 4 at paragraph 342.
75 See in particular: section 1.7; section 1.3; section 1.4; section 1.1.
• there is now a mechanism to make information available about unapproved products and/or indications via a medical information website, subject to certain guidelines

• clarification that companies must not promote that a product will be listed on, for example, the PBS prior to receiving written advice from the Department of Health stating the listing date.

278. Section 3 of the Code addresses the Product Information which is included with promotional material for healthcare professionals. Amendments include:

• an explicit requirement that the Minimum Product Information must be reviewed and updated in a timely manner following a change to the Product Information

• removing the specifications of the manner in which a change of clinical significance is communicated to healthcare professionals, and providing that companies must communicate a change to the Product Information in accordance with any direction from the TGA.

279. Medicines Australia submits that amendments included in edition 18 of the Code ensure that member companies can determine with ease, clarity and specificity how they may present their promotional claims. Medicines Australia submits that the Code ensures that healthcare professionals have up to date and accurate information in relation to medicines prescribed by them and that healthcare professionals always have access to detailed prescribing information about products, in a targeted way not done easily in legislation.

280. Medicines Australia submits that these amendments continue to ensure that a high, consistent and industry-specific standard for medical and promotional claims is sustained and results in further public benefits relative to edition 17.

Interested parties

281. The Department of Health supports permitting companies to make information (which is not promotional) about unapproved products and indications available through a public website, and requirements regarding currency of information to reflect a change in the TGA approved Product Information.

282. The Department of Health also submits that while the current Code refers to a general commitment to Quality Use of Medicines and rational prescribing, it is now timely to consider the inclusion of stand-alone provisions within the Code to address antimicrobials, and in particular, antibiotics. The Department of Health suggests that the Code ensure that companies provide accurate information to providers, dispensers, and the general public that stresses the importance of the judicious use of antimicrobials. Further, advertising and promotional material and Product Information relating to antimicrobial products should acknowledge that inappropriate prescribing and use may contribute to the emergence of antimicrobial resistance.

283. The CHF supports the strengthening of sections related to the promotion of unapproved products or indications. The CHF supports the additional requirements

76 See in particular sections 3.2 and 3.3 of the Code.
to ensure that adequate safety information is included in relation to efficacy or other promotional claims. The CHF also supports additional media requirements to cover electronic media such as smartphone applications, electronic tablets and other mobile devices and software.

284. The SHPA submits that if Product Information was available for all registered and listed medicines this would dramatically improve and support the appropriate advertising of therapeutic goods. The SHPA also has concerns regarding advertising via the internet, email, SMS and MMS.

285. In response, Medicines Australia notes that Product Information and Consumer Medicine Information are governed by the TG Act and the Code goes further than the legislation. Medicines Australia submits that the Code already covers electronic advertising. The Code and the TG Act prevent promotion to the general public, including via the internet, email, SMS and MMS.

**ACCC view**

286. As noted by Medicines Australia, the Tribunal previously found there was substantial public benefit in the provisions which set standards for medical and promotional claims. The ACCC has previously agreed that medical practitioners might not always possess perfect information on the range of remedies available and may not have sufficient time to absorb the volume of scientific studies and research available on pharmaceutical products. As a result medical practitioners might rely heavily on information provided by pharmaceutical manufacturers and it is important this information is balanced and accurate.

287. While there are general legislative prohibitions on misleading and deceptive conduct, the ACCC notes that the standards in the Code are specific to pharmaceuticals and that their breach will trigger possible disciplinary action and sanctions under the Code. For these reasons, the ACCC considers that such provisions, as amended in edition 18, will continue to give rise to public benefits.

288. The ACCC considers that the suggestion raised by the Department of Health that a section regarding antibiotics be included in the Code is best addressed between the Department of Health and Medicines Australia directly, and is not proposing to address these matters in the current authorisation process.

**v. Internal compliance procedures for pharmaceutical companies**

289. Medicines Australia submits that the Code provides stringent requirements in relation to member companies implementing internal training and compliance procedures to ensure staff are appropriately trained in relation to, and comply with, the Code.

290. Medicines Australia notes that the Code imposes training and knowledge requirements on various industry participants. Company representatives are required to (a) possess sufficient medical and technical knowledge to present information on the company’s products in a current, accurate and balanced manner.

---

77 Re Medicines Australia Inc [2007] ACompT 4 at paragraph 342.
78 See in particular sections 5, 6 and 39 of the Code.
and (b) to be cognisant of all provisions of the Code. Medical representatives are also required to undertake the endorsed Medicines Australia education program.

291. Anyone directly involved in the development, review and approval of promotional and educational materials for the general public or who has direct interaction with healthcare professionals regarding prescription products is required to complete the Code component of the education program and regular training on privacy and competition and consumer legislation.

292. These sections are not amended in edition 18 of the Code.

**ACCC view**

293. The ACCC agrees that imposing training and knowledge requirements on various industry participants is likely to assist in ensuring their interactions with the public, healthcare professionals and other parties are appropriate. The ACCC considers that an internal compliance program to ensure that company representatives are not only aware of the Code, but comply with the Code and maintain a level of professionalism in their dealings with healthcare professionals, will also result in a public benefit.

**vi. Administration, monitoring and enforcement**

294. In its review of previous editions of the Code, the ACCC has noted that any public benefits associated with the substantive provisions of the Code will only arise to the extent that the Code is effective in its operation. In relation to edition 18 of the Code, interested parties have raised particular concerns about:

- the effectiveness and consistency of sanctions under the Code
- the absence of a full pharmacist member on the Monitoring Committee.

295. Medicines Australia submits that relevant revisions in edition 18 of the Code include:

- a new preamble in relation to Code administration
- clarifying the relationship between the Code and the Medicines Australia Constitution, and between the Medicines Australia Board and the Monitoring, Code of Conduct and Code of Conduct Appeals Committees
- providing a discretion for the acceptance of complaints where the issue is also the subject of legal proceedings between the relevant parties
- clarifying the membership of the committees
- amending the types of review undertaken by the Monitoring Committee in order to continue to ensure that that committee operates effectively.

296. The effectiveness of the Code is dealt with under the following headings:

- The effectiveness of the Committee and the code administration
• Complaints process
• Effectiveness of sanctions under the Code.

The effectiveness of the Committees and the code administration

297. Medicines Australia submits that it actively promotes understanding of the Code and seeks to reduce non-compliance. Relevantly, Medicines Australia submits that the Code provides for three committees and a Secretariat. In addition, Medicines Australia publishes written Code Guidelines, conducts other formal training and education sessions, and provides informal guidance on the operation of the Code.

298. The roles of the committees are as follows:

• The Monitoring Committee – proactively monitors the promotional material and conduct of member companies, in order to promote compliance with the Code and therefore support the Quality Use of Medicines (the Monitoring Committee is discussed further below).

• The Code Committee – supervises the administration of the Code and is accountable to the Medicines Australia Board; hears and determines complaints against member companies and non-members who agree to have a complaint adjudicated by the Code Committee; and is empowered to impose sanctions for breaching the Code.

• The Appeals Committee – hears appeals against findings and/or sanctions imposed by the Code Committee and is responsible to the Medicines Australia Board.

299. Edition 18 of the Code clarifies certain processes for these committees, such as the requirements for a properly constituted meeting, appointments, membership and attendance by observers and the Secretariat.

300. The Department of Health considers that there could be further clarity around determining conflict of interest of members of the Committees.

301. Medicines Australia submits that it regularly engages in communication activities to raise awareness, promote understanding of the Code and encourage compliance; for example, by meeting with pharmaceutical companies, healthcare professional organisations, consumers, health consumer organisations and agencies, and businesses working with the industry. During the last financial year Medicines Australia staff participated in 34 communication activities with a total audience of 906 people.

302. Further, Medicines Australia submits that the Secretariat now provides regular monthly training webinars for any member company, non-member company or agency personnel, in addition to webinars on specific topics when required.

303. The Code Guidelines are also prepared to provide assistance to companies in complying with the Code. The Guidelines are regularly updated as issues arise or when requested and will be updated to reflect the new transparency requirements.

304. Medicines Australia submits that it responds to many requests for informal guidance and advice on the Code from member and non-member companies,
healthcare professionals, consumer organisations, members of the public, the media and agencies working in the healthcare sector.

ACCC view

305. The ACCC has previously accepted that promotion of the Code by Medicines Australia through both formal and informal measures increases the effectiveness of the Code. The ACCC has not received any submissions which indicate that this has changed since the ACCC authorised edition 17 (or previous editions) of the Code.

306. The ACCC acknowledges that Medicines Australia has included a consumer representative and a healthcare professional representative, nominated by the CHF and the AMA respectively, on the Code Review Panel, consistent with its undertaking in 2012.

The Monitoring Committee

307. Edition 18 specifies that each financial year the Monitoring Committee conduct:

- a minimum of three reviews of promotional materials within one or more therapeutic classes
- a minimum of three reviews of different activities across all therapeutic classes
- reviews of the educational meetings and symposia data provided by member companies.

308. Under edition 18, a member company will only be required to provide promotional materials or information on no more than three occasions during a calendar year.

309. Medicines Australia considers that these amendments ensure that the Monitoring Committee continues to undertake a detailed and effective review of the activities of member companies while ensuring the scope of that review is not unduly burdensome.

310. Medicines Australia submits that in recent years the Monitoring Committee has seen an increased level of compliance with the Code by member companies. The activities of the Monitoring Committee in 2013/14 are shown below.

Figure 1: Summary of materials and activities reviewed by the Monitoring Committee in 2013/14 (source: Medicines Australia, Outcomes of Monitoring Committee Reviews, 2013-2014)

<table>
<thead>
<tr>
<th>Therapeutic Class</th>
<th>Types of material subject to review</th>
<th>Number of companies</th>
<th>Number of items</th>
<th>Number of meetings to undertake review</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cardiovascular System</td>
<td>Ads in audiovisual, internet, eNewsletters</td>
<td>8</td>
<td>29</td>
<td>1</td>
</tr>
<tr>
<td>Alimentary</td>
<td>Printed Promotional Material</td>
<td>6</td>
<td>20</td>
<td>1</td>
</tr>
<tr>
<td>Eye Patient Education</td>
<td>3</td>
<td>11</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>----------------------</td>
<td>---</td>
<td>----</td>
<td>---</td>
<td></td>
</tr>
<tr>
<td>Central Nervous System</td>
<td>14</td>
<td>36</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>Musculoskeletal System</td>
<td>6</td>
<td>8</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>Neoplastic Disorders</td>
<td>17</td>
<td>39</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>All therapeutic classes</td>
<td>32</td>
<td>357</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>TOTAL</td>
<td>86</td>
<td>500</td>
<td>7</td>
<td></td>
</tr>
</tbody>
</table>

311. The Department of Health expects that, with respect to recent amendments to the Code, Medicines Australia’s Monitoring Committee and Complaints Committee will take an active role in monitoring and responding to compliance issues and reporting unintended consequences. In particular, the Department of Health refers to the changes regarding: websites for unapproved products/indications; requirements for minimum Product Information; product labels for starter packs; and the new transfer of value reporting.

312. The PSA submits that there should be the inclusion of a full pharmacist member on the Monitoring Committee.

313. In response, Medicines Australia submits that although the Monitoring Committee does not currently include a pharmacist as a full member, its membership is broad. Also, a representative of the Guild, the PSA or the SHP is eligible to be a full member of the Code Committee and Appeals Committee where a complaint relates to activities directed at a pharmacy.

**ACCC view**

314. The ACCC considers that the effectiveness of the Code relies on Medicines Australia becoming aware of any breaches. In particular, the activities of the Monitoring Committee should be sufficient to identify breaches. No submissions have been received to indicate that this is not the case.

315. The ACCC also notes the submission of the Department of Health that Medicines Australia’s Monitoring Committee and Complaints Committee should monitor compliance with new requirements of the Code. The ACCC agrees with this sentiment. Any other measures that Medicines Australia takes to ensure that the Monitoring Committee effectively identifies breaches of the Code will further increase the chance of the benefits arising.

316. The ACCC notes the PSA’s request for the inclusion of a full pharmacist member of the Monitoring Committee. The ACCC accepts Medicines Australia’s submission that membership of this committee is broad and also notes that it may not always be possible to represent all interests on such committees.

---

79 See in particular: section 41; sections 3.2 and 3.3; section 7.8; section 1.4.
Complaints process

Medicines Australia submits that its complaints process provides an appropriate forum for the adjudication of complaints, noting that the membership of the Appeals Committee is diverse and flexible and conflicts of interest are identified.

Amendments in edition 18 of the Code include:80

• where a complaint is also the subject of legal proceedings in an Australian court or Administrative Tribunal, Medicines Australia has the discretion to either not accept a complaint or delay referring it to the Code Committee

• Medicines Australia has the discretion to not accept a complaint that has already been substantially dealt with by the Code Committee

• guidelines for complainants including non-industry generated complaints. Also, the Secretariat will always offer the services of an independent facilitator to assist a non-industry complainant to identify relevant sections of the Code. This will reduce the potential burden on non-industry complainants by ensuring that they have access to assistance in formulating their complaints

• additional clarity on the process for industry generated complaints by requiring a record of meeting to be submitted to Medicines Australia and the senior executive officer of the companies involved.

Medicines Australia submits that these provisions in the Code help ensure that the complaints process is effective for industry and non-industry complaints alike and that the public benefits associated with the process remain substantial.

Medicines Australia considers that its complaints process is accessible to complainants, as demonstrated by the variety of stakeholders who have lodged complaints. Between 2008/2009 and 2012/2013, 23 percent of complaints were from healthcare professionals, 5 percent from organisations, 33 percent from the Monitoring Committee, 32 percent from pharmaceutical companies and 7 percent from other stakeholders. Further, the complaint form is readily available from the Medicines Australia website and is easy to understand.

Medicines Australia notes that in 2012/2013, the average time to resolve a complaint was 34 working days (or 27 working days where the complaint was not subject to an appeal), down from 41 working days in 2009/2010.

Medicines Australia notes that any potential contraventions of the Code identified by the Monitoring Committee are referred to the Code Committee as a complaint. The table below lists the complaints received by the Code Committee from 2008/2009 to 2013/2014.

---

80 See in particular section 20.1 and Appendix 1 to the Code.
Figure 2: Complaints received by the Code Committee from 2008/09 to 2013/14
(source: Medicines Australia supporting submission; Code of Conduct Annual Report 2013-2014)

<table>
<thead>
<tr>
<th>Source/ Year</th>
<th>2008/09</th>
<th>2009/10</th>
<th>2010/11</th>
<th>2011/12</th>
<th>2012/13</th>
<th>2013/14</th>
</tr>
</thead>
<tbody>
<tr>
<td>Healthcare professionals</td>
<td>11</td>
<td>8</td>
<td>4</td>
<td>6</td>
<td>3</td>
<td>2</td>
</tr>
<tr>
<td>Organisations (e.g. TGA, College/Society, Consumer Organisations)</td>
<td>6</td>
<td>1</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Other (general public and academics)</td>
<td>2</td>
<td>6</td>
<td>2</td>
<td>0</td>
<td>0</td>
<td>1</td>
</tr>
<tr>
<td>Monitoring Committee</td>
<td>26</td>
<td>14</td>
<td>2</td>
<td>2</td>
<td>3</td>
<td>2</td>
</tr>
<tr>
<td>Pharmaceutical Companies (member and non-member companies)</td>
<td>14</td>
<td>10</td>
<td>6</td>
<td>4</td>
<td>12</td>
<td>5</td>
</tr>
<tr>
<td>Total</td>
<td>59</td>
<td>39</td>
<td>14</td>
<td>12</td>
<td>18</td>
<td>10</td>
</tr>
</tbody>
</table>

Medicines Australia submits that the number of complaints received by the Code Committee has progressively decreased from 59 in 2008/09 to 18 in 2012/13. The number of complaints referred to the Code Committee by the Monitoring Committee has also decreased since 2008/09, despite the fact the Monitoring Committee continues to review a large number of promotional materials each year. Further, there have been no complaints in the last two financial years from organisations such as the TGA or healthcare professional societies and no complaints from members of the general public or academics. The largest number of complaints continues to come from pharmaceutical companies.

**ACCC view**

The ACCC accepts that, based on the data above, the number of complaints has generally been decreasing in the past five years.

The ACCC has previously expressed concerns, in authorising previous editions of the Code, that an onerous complaints process may decrease the effectiveness of the Code. Relevantly, the fact that there have been no complaints from members of the general public or academics in the past two financial years could either suggest that these individuals do not have concerns, or it could indicate a reluctance to use the complaints process. However the ACCC has not received submissions from interested parties on this issue in the current reauthorisation process.

If in the future the complaint procedures were shown to be ineffective this would be of significant concern to the ACCC. In authorising edition 17 of the Code, the ACCC recommended that Medicines Australia should review its complaints procedures in future reviews of the provisions of the Code to ensure that they do not become overly onerous on complainants, and that procedural fairness is afforded to all complainants. The ACCC noted that the ability for the public to make complaints is an important feature of increasing the transparency around the relationship of the pharmaceutical industry with healthcare professionals.
327. The ACCC considers that clarification in edition 18 of the Code that a facilitator will always be offered to a non-industry complainant is a step in the right direction, as is ensuring that the complaints form is easy to understand and readily available on Medicines Australia’s website. Medicines Australia should continue to consider further incremental improvements in future editions of the Code, as appropriate.

**Effectiveness of sanctions under the Code**

328. Medicines Australia submits that the power of the Code Committee to impose sanctions is a public benefit. The sanctions available are: modification or discontinuance of a practice; publishing corrective statements; and paying fines.

329. Medicines Australia notes that, as a general rule, moderate to severe breaches will require corrective action. Medicines Australia can also forward a complaint/appeal to the TGA or the ACCC if a subject company does not pay a fine within 30 days, and publicise the failure to comply.\(^\text{81}\)

330. The maximum fine under the Code for severe or repeated breaches is up to $250,000, with a cumulative maximum of $300,000 per complaint. The maximum fines have not been amended in edition 18 of the Code.

331. Medicines Australia submits that the imposition of fines for breaches of the Code is the norm. Sanctions imposed in 2013/14 are summarised in the below graphs.\(^\text{82}\)

*Figure 3: Sanctions imposed by the Code and Appeals Committees on companies with complaints found in breach and finalised in 2013-14 (source: Medicines Australia Code of Conduct Annual Report 2013-2014)*

---

\(^{81}\) See sections 28.2 and 28.3 of the Code.  
\(^{82}\) The Code Committee found that six companies had contravened the Code and in each case a fine was imposed. The two largest fines were $250,000.
332. The CHF queries whether the level of financial penalties is sufficient, noting that penalties in other countries are substantially higher and that some companies continue to breach the Code (based on the Code of Conduct Annual Report 2013).

333. Medicines Australia does not consider that the quantum of fines/sanctions should be amended. Previously, Medicines Australia has pointed to the high level of fines under the Code compared to other codes (e.g. the GMiA Code of Practice) and noted that the Code allows for non-monetary penalties. Medicines Australia suggested these sanctions are taken seriously by member companies. Medicines Australia submits that the Monitoring Committee has seen an increased level of compliance with the Code by member companies in recent years, which demonstrates the effectiveness of existing sanctions.

334. Medicines Australia submits that it provides transparency in relation to outcomes of the complaints process by preparing quarterly reports, a Code of Conduct Annual Report, and in the case of complaints relating to an activity directed at the general public, publishes details on its website.

**Publicising breaches of the Code**

335. In the draft determination, the ACCC queried whether important decisions should be circulated in the form of a media release, in addition to the existing reporting and web updates.

336. Medicines Australia submits that it is neither necessary nor appropriate to require a press release in respect of decisions by the Code or Appeals Committees to impose a fine on member companies who contravene the Code, noting the existing reporting and that this would effectively act as a further penalty.

337. Dr Harvey notes that there are other mechanisms for this information to be distributed but nonetheless supports media releases on breaches of the Code to encourage coverage in the lay media. The CHF and the PHAA likewise support the introduction of media releases on breaches of the Code. The CHF submits that
better publication of breaches of the Code would assist with assessing the effectiveness of the Code.

338. In the February consultation, the ACCC did not include any requirements to better publicise breaches of the Code but the ACCC noted that Medicines Australia should consider this issue prior to any future application for reauthorisation.

**ACCC view**

339. As in 2012, the ACCC notes that it is difficult to determine whether the existing level of fines is appropriate. It is clear that the low level of fines available under the Code would not be substantial enough by themselves to deter a profitable breach, given the low probability of a breach being detected and a fine being imposed. The ACCC would be concerned if it was provided with specific evidence of systemic breaches of the Code as this would undermine the effectiveness of the Code. To date the ACCC has not received any submissions which detail specific evidence of systemic breaches of the Code.

340. The ACCC notes that financial sanctions are part of a package of disciplinary measures. Further, under the Code, member companies are required to cease any activities that are deemed to breach the Code.

341. It is not clear whether the reduced number of complaints is directly related to the effectiveness of the monetary fines. However given the apparent level of compliance with the Code reported by Medicines Australia, the ACCC accepts that the monetary and non-monetary sanctions currently available under the Code (together) likely provide an effective deterrence against breaches of the Code by member companies. The potential for a legislative response by government if breaches were to become systemic is likely to deter companies from breaching the voluntary code. The potential for public criticism surrounding the imposition of a fine may also increase the effectiveness of the fine itself.

342. In order for public criticism to be an effective deterrent, decisions to impose a fine should be adequately publicised.

343. The ACCC has decided not to impose a condition in respect of this issue at this time. However, prior to any application for reauthorisation, the ACCC expects Medicines Australia to look at ways to better publicise breaches of the Code.

344. The ACCC accepts that the fines must be kept at an effective level and encourages Medicines Australia to maintain fines at a level such that the fines and their enforcement deter any breaches of the Code.

**ACCC conclusion on public benefits**

345. The ACCC accepts that the following public benefits are likely to result from edition 18 of the Code, when effectively monitored and enforced:

- Addressing the principal agent problem and the scope for the prescribing practices of healthcare professionals to be disproportionately influenced (subject to the conditions of authorisation – see paragraphs 359 to 437). The Code does this by outlining the boundaries for appropriate relationships between pharmaceutical companies and healthcare
professionals to limit the potential for conflicts of interest and opening these relationships to public scrutiny by requiring the reporting of transfers of value.

- Reducing the potential for conflicts of interest that may arise between pharmaceutical companies and health consumer organisations and patients by providing for greater transparency around these relationships and regulating, for example, Patient Support Programs.

- Encouraging compliance with legislation and protecting the general public from inappropriate advertising.

- Ensuring medical practitioners (who may be subject to bounded rationality or information asymmetry) can rely on information provided by pharmaceutical manufacturers by setting consistent standards for medical and promotional material thereby reducing misleading claims about medicines.

- ensuring industry participants interact appropriately with other parties by imposing training and knowledge requirements and requiring pharmaceutical companies to have an internal compliance procedure promoting compliance by all company employees.

346. The ACCC accepts that there are significant public benefits arising from various sections of the Code and is satisfied that, overall, the conduct the subject of the authorisation results in significant public benefits. However the ACCC considers there to be serious flaws in the operation of the transparency regime, which the ACCC considers are likely to significantly undermine the transparency benefits of the Code.

Public detriment

347. Public detriment is also not defined in the Act but the Tribunal has given the concept a wide ambit, including:

...any impairment to the community generally, any harm or damage to the aims pursued by the society including as one of its principal elements the achievement of the goal of economic efficiency.\(^\text{83}\)

348. Medicines Australia submits there is minimal potential anti-competitive or other public detriment identifiable in edition 18 of the Code, and that minimal detriment is substantially outweighed by the already existing public benefits associated with the Code, which will be significantly strengthened following the amendments in edition 18.

349. The RACGP, Dr Harvey and CHOICE submit that the transparency in edition 18 of the Code is not an incremental improvement and its authorisation would result in public detriment.

350. The ACCC notes that anti-competitive detriments may arise insofar as the Code limits the ability of companies to freely compete with each other through the advertising and promotion of their products, particularly to healthcare professionals.

\(^{83}\) \textit{Re 7-Eleven Stores} (1994) ATPR 41-357 at 42,683.
In particular, the ACCC notes the detailed provisions regulating member conduct in relation to promotional activities and material directed at healthcare professionals (including brand name reminders) and relationships with healthcare professionals. The ACCC also notes that the administration and enforcement of the Code, as well as the requirement for certain persons to participate in an education program endorsed by Medicines Australia, may give rise to anti-competitive detriment.

351. However, the ACCC considers that the Code includes such restrictions as a means for addressing market failures which may arise in the health sector.

352. The Tribunal was satisfied in its consideration of edition 15 of the Code that ‘there is little in the way of significant anti-competitive detriment’ resulting from the Code and that the:

...restrictions imposed by the Code do not strike at the heart of competitive conduct as to price and quality and lawful communications of the benefits and characteristics of pharmaceutical products to appropriately qualified healthcare professionals.  

353. The ACCC considers that this remains the case for edition 18 of the Code.

ACCC conclusion on public detriments

354. The ACCC considers that any anti-competitive detriment resulting from the Code is likely to be minimal. While the Code restricts to some degree the promotional activities of Medicines Australia members and non-members, the ACCC accepts that the Code does this to address potential market failures which may arise.

Balance of public benefit and detriment

355. The ACCC may grant authorisation if it is satisfied that, in all the circumstances, the proposed conduct is likely to result in a public benefit, and that public benefit will outweigh any likely public detriment, including any lessening of competition.

356. In the context of applying the net public benefit test in subsection 90(8) of the Act, the Tribunal has commented that:

... something more than a negligible benefit is required before the power to grant authorisation can be exercised.

357. For the reasons outlined in this determination, the ACCC is satisfied that the likely benefit to the public would outweigh the detriment to the public including the detriment constituted by any lessening of competition that would be likely to result. However, the ACCC retains concerns about the operation of the transparency regime proposed in the Code, including the accessibility of data reported, which it believes is likely to significantly undermine the transparency benefits of the Code.

84 Re Medicines Australia Inc [2007] ACompT 4 at paragraph 333.
85 The test at subsection 90(8) of the Act is in essence that conduct is likely to result in such a benefit to the public that it should be allowed to take place.
86 Re Application by Michael Jools, President of the NSW Taxi Drivers Association [2006] ACompT 5 at paragraph 22.
Accordingly, while the ACCC is satisfied that the relevant net public benefit tests are met, the ACCC is imposing the conditions of authorisation set out below.

**Conditions of authorisation**

359. Subsection 91(3) of the Act allows the ACCC to grant authorisation subject to conditions specified in the authorisation.

360. The power conferred upon the ACCC to authorise conduct is discretionary. In exercising that discretion, it may have regard to considerations relevant to the objectives of the Act.

361. The ACCC may impose a condition in circumstances where, although the relevant public benefit test is met without the condition, the ACCC would not be prepared to exercise its discretion in favour of authorisation. Where there is limited public detriment (as in the case of the present application) the ACCC can impose a condition to yield a more substantial public benefit or to enhance the likelihood that the public benefit will be realised.

362. As noted, following the draft determination and the pre-decision conference, in February 2015, the ACCC consulted with Medicines Australia and interested parties on five revised proposed conditions of authorisation (subject to modifications). (One of these revised proposed conditions included an amended version of the condition proposed in the draft determination). A copy of the proposed revised conditions circulated on 6 February 2015 is available from the ACCC’s website at: www.accc.gov.au/authorisationsregister.

363. The ACCC has decided to impose these five conditions of authorisation (subject to some modification). In essence, the conditions are imposed to:

- ensure all relevant transfers of value are reported
- require that the transparency data is reported in a common accessible format
- require Medicines Australia to use reasonable endeavours to implement a central reporting system and to report six monthly on its progress in doing so
- require publication and retention of reports for three years instead of two
- provide for future non-material amendments to the conditions.

---

87 Application by Medicines Australia Inc (2007) ATPR 42-164 at paragraph 106.
88 Application by Medicines Australia Inc (2007) ATPR 42-164 at paragraph 126.
89 Application by Medicines Australia Inc (2007) ATPR 42-164 at paragraph 133.
90 Application by Medicines Australia Inc (2007) ATPR 42-164 at paragraph 128.
91 The ACCC received submissions from: Medicines Australia; ASCEPT; the RACGP; Professor Del Mar; the AMA; Pfizer; the CHF; the SHPA; the RANZCP; the ASA; Dr Smith; Dr Purssey; Dr Harvey; Professor Morris. Medicines Australia, ASCEPT, the RACGP and Professor Del Mar submit that they are generally supportive of the revised proposed conditions.
364. The ACCC has decided not to impose conditions with respect to food and beverage expenditure reporting, publicising breaches of the Code, and including the drug name in transparency reporting.

365. The conditions in full are provided at Attachment B. The submissions received commenting on the conditions of authorisation and the ACCC’s approach are summarised below.

**Condition 1: Reporting of all relevant transfers of value**

366. The ACCC proposed a condition in the draft determination requiring Medicines Australia to amend the Code to require members, prior to making a relevant transfer of value (as defined in 41.3.1 of the Code), to either (i) obtain the consent of a healthcare professional to the disclosure of information, or (ii) take appropriate steps to give notice of the disclosure obligation so that the healthcare professional would reasonably expect the disclosure.

367. The proposed condition was designed to increase public access to, and scrutiny of, meaningful information about benefits provided by medicines companies to healthcare professionals. In particular, it addresses the key deficiency of the proposed transparency regime (that is, disclosure of individual transfers of value being contingent on the consent of healthcare professionals to that disclosure) and was intended to enhance the likelihood that potential public benefits resulting from the transparency reporting provisions of the Code would be realised. These benefits are described in section 41.3 of the Code as:

> …to provide visibility for consumers of payments and transfers of value to healthcare professionals who are engaged in patient care.

368. Most of the submissions received in response to the draft determination and at the pre-decision conference supported the proposed condition (none opposed it).

369. As noted at paragraphs 135 to 136, in response to a request by Medicines Australia, on 8 April 2014, the Privacy Commissioner provided advice in relation to matters in respect of Australian privacy legislation. On 18 November 2014, the Privacy Commissioner provided a further submission, stating that he did not have any concerns about the ACCC’s proposed condition requiring pharmaceutical companies to either obtain a healthcare professional’s consent, or give notice so that the healthcare professional would reasonably expect the disclosure, before making the transfer of value.

370. Medicines Australia and the AMA queried whether the proposed condition would affect the ability for a healthcare professional to withdraw their consent to disclosure after receiving a transfer of value, having regard to Australian privacy legislation. Medicines Australia submitted that, where a healthcare professional consented to disclosure, received transfers of value and then withdrew consent to disclosure, the transfers should not be individually reported and should instead be reported in aggregate.

371. Professor Morris, the PHAA, the CHF and the RACGP were concerned about the ability of a healthcare professional to withdraw their consent after receiving a transfer of value.
372. Professor Morris suggested relying on member companies creating reasonable expectation of disclosure by healthcare professionals (rather than taking a consent based approach) as a way of ensuring universal disclosure in accordance with Australian privacy legislation. Medicines Australia submitted that the Privacy Commissioner’s advice is not legal advice and does not provide complete comfort. The AMA was also concerned that reasonable expectation is a difficult test to meet.

373. Subject to its comments in relation to the withdrawal of consent, referred to above, Medicines Australia submitted that such a significant change to the Code must not be rushed. It proposed that the transparency regime currently contained in edition 18 of the Code should be allowed to be implemented for up to a 12 month period from 1 October 2015 to 1 October 2016, with the amendments to the Code required by the ACCC’s proposed condition not required until 1 October 2016.

374. The AMA, Sanofi, Celgene, Novo Nordisk, Novartis, Pfizer and Bristol-Myers Squibb also supported this delay.

375. The RACGP, the PHAA, the CHF, Professor Morris and Dr Harvey did not support the delay.

376. Following the draft determination, the ACCC considered amending the proposed condition to require member companies not to make transfers of value to healthcare professionals unless they have taken appropriate steps such that healthcare professionals reasonably expect disclosure of transfers of value made to them. This would remove the option for member companies to obtain a healthcare professional’s consent to disclosure of information about transfers of value made (i.e. sub-paragraph (i) of the condition proposed in the draft determination). In doing so, the amendment would avoid difficulties which may arise in reporting a transfer of value in circumstances where a healthcare professional consented to disclosure, received a relevant transfer and then withdrew consent before the transfer was reported.

377. The ACCC also acknowledged Medicines Australia’s concern that such a change to the Code is significant and should not be rushed. The ACCC therefore accepted Medicines Australia’s request to extend the deadline for making the amendments to section 41.3.2 until 1 October 2016. The transparency regime originally proposed by Medicines Australia (and currently contained in edition 18 of the Code), would operate from 1 October 2015 until Medicines Australia amends section 41.3.2 in accordance with the condition. The ACCC noted it expected Medicines Australia to prepare for this change in advance to ensure it meets this timeframe.

378. The ACCC consulted on these matters as part of the February consultation. The submissions received support the revised condition and do not object to a 12 month delay in implementation.

**ACCC view**

379. The ACCC sees important benefits from the reporting of transfers of value provided to healthcare professionals on an individual basis – see, for example, paragraphs 147 to 149 above. For the reasons outlined at paragraphs 146 to 163 the ACCC considers universal disclosure of relevant transfers made to healthcare professionals is key to the utility of the broader transparency regime.
380. The ACCC is concerned that the transparency regime proposed by Medicines Australia in edition 18 of the Code would enable member companies to provide benefits to healthcare professionals without reporting the benefits (where healthcare professionals do not consent to the benefits being reported).

381. In order to secure universal reporting, and the associated public benefits, while having regard to Medicines Australia’s concern that its members comply with Australian privacy legislation, the ACCC has decided to impose the revised condition in the form consulted on in February (i.e. the condition proposed in the draft determination but without the option for a member company to obtain a healthcare professional’s consent to disclosure and including additional time for implementation) (see condition 1, Attachment B).

382. To ensure that Medicines Australia and its member companies meet this deadline, the ACCC considers they should prepare well in advance for the transition to the reporting of all transfers of value, and in fact should be ready to move to the new regime well before 1 October 2016. In these circumstances, the ACCC expects that Medicines Australia would amend section 41.3.2 before the 1 October 2016 deadline. This would ensure that any unexpected events do not result in a delay beyond this date and jeopardise the ability of Medicines Australia to meet that date and thereby comply with this condition of authorisation. This provides a significant lead-in time to be ready for its introduction and the ACCC does not expect any further delays in its implementation.

383. The ACCC also expects that Medicines Australia and member companies will take steps to ensure that the delay in implementing the new transparency regime will not result in the public or healthcare professionals being misled or confused.

384. Edition 18 of the Code as currently drafted gives healthcare professionals the option not to consent to disclosure of their information and will be in effect until Medicines Australia adopts Condition 1. Therefore the ACCC notes that initially healthcare professionals will be able to opt out of disclosure if they do not provide consent, and then the regime will transition to a system where all relevant transfers of value will be reported. In this regard, the ACCC notes that:

- transparency reports published in the period between 1 October 2015 and the amendment of section 41.3.2 by Medicines Australia may not contain details of all relevant transfers of value made to individual healthcare professionals (since some healthcare professionals may not provide consent for individual transfers to be reported). The ACCC expects member companies to make clear any such limitations when publishing these reports
- it is likely that the first report made after the amendment to section 41.3.2 will contain information about transfers of value made both before and after the amendment. Accordingly, it will not include information about transfers of value made before the amendment, where the receiving healthcare professionals did not consent to disclosure. Again, member companies will need to make clear any such limitations when publishing the report
- it will be important that healthcare professionals appreciate that the ability to accept a transfer of value but not consent to its disclosure will be only temporary.
The ACCC also expects that:

- member companies will take appropriate steps to ensure that, upon the amendment of section 41.3.2 (by no later than 1 October 2016), healthcare professionals reasonably expect that all transfers of value they receive will be reported.

- Medicines Australia (as it proposed to do in respect of the current concept of ‘informed consent’ in section 41.3.2), will provide guidance to its members to assist them in complying with the new reporting requirements in section 41.3.1 and the steps that they will need to take to ensure, prior to making a transfer of value, that it meets the new requirements in section 41.3.2.

**Condition 2: Common reporting format**

In the draft determination the ACCC did not propose the format to be used by member companies when reporting the individual transparency data.

Following the draft determination, the ACCC considered whether it should require Medicines Australia to amend the Code to require member companies to report in a standard template and in an identical accessible format (i.e. Microsoft Excel) to facilitate public access to and scrutiny of the reported data, which is otherwise spread across multiple member company websites. The ACCC consulted on such a possible condition in the February consultation.

Medicines Australia, Pfizer and the AMA object to a requirement that transparency data must be reported in Excel format for several reasons.

In a detailed submission of 16 March 2015, Medicines Australia expressed the view that it is not necessary to use a format that can be modified and that such a format could pose security concerns as third parties could access, disclose/re-publish, extract and modify information for purposes unrelated to those for which the data was collected. Medicines Australia submitted that the purposes for which member companies would be disclosing the relevant information are the benefits of transparency identified in the draft determination, namely:

- having the potential to address the principal-agent problem, by giving patients some transparency over a matter which may influence the objectives of their prescribing healthcare professional

- being aware of transfers of value received by a particular healthcare professional may alert a patient to a possible influence on their healthcare professional’s prescribing decisions

- enabling fellow healthcare professionals to inform themselves about matters which may be relevant to their understanding of, for example, a key opinion leader in their field

- deterring member companies from making, and healthcare professionals from accepting, transfers of value which may raise conflicts of interest, if the transfers are subject to public scrutiny.
390. Medicines Australia submitted that Australian privacy legislation requires member companies to take reasonable steps to prevent the information being used for any purpose other than those for which the information was collected, which are the purposes relating to transparency outlined in paragraph 389 above. It submitted that publishing the information in a format which does not allow the data to be extracted and modified (such as a readable and searchable PDF) would achieve the benefits of transparency identified above and accordingly that, by publishing personal information in a way that allowed the data to be extracted, modified or disclosed by third parties (such as in Excel format), member companies would not be taking the ‘reasonable steps’ required, which could put them at risk of breaching privacy legislation.

391. In addition, Medicines Australia said that member companies should not be restricted to use a particular proprietary spreadsheet program nor dissuaded from developing other disclosure platforms. Medicines Australia also objected to requiring strict adherence to the reporting template as companies may wish to insert additional fields or Medicines Australia may want to amend the template. Medicines Australia accepted that reports should be searchable and that the reports published by individual member companies must display all of the data (rather than relying on a search function that only displays a sub-set of the full data). Pfizer supports these views.

392. The AMA supports use of a standard template, but objects to a reporting format that allows searching of the data beyond enabling patients to search for a specific practitioner because this could allow data ‘trawling’ for use out of context.

393. On 26 February 2015, the ACCC sought clarification of the applicable obligations under the Australian Privacy Principles (APPs) from the Australian Privacy Commissioner. In his response of 26 March 2015, the Australian Privacy Commissioner noted that:

- one basis on which information can be used and disclosed is where it is for a purpose related to the primary purpose of collection and the individual would reasonably expect their information to be used or disclosed for that purpose. The Privacy Commissioner noted that member companies will rely on this basis to disclose the data in question

- for the transparency data published on a member company’s website, the member company needs to take reasonable steps to protect that information from being modified while it is held on its website

- the obligation to protect against misuse does not extend to protecting against unauthorised use by a third party who collects the data from the website and subsequently uses that information

- to the extent that third parties who access the information from a member company’s website are themselves bound by Australian privacy legislation, they must comply with the APPs in relation to their collection and subsequent handling of the information. For example, they can only collect the information if it is reasonably necessary for their functions or activities and their use and disclosure of the information must be permitted by the APPs.
394. On 1 April 2015 the ACCC consulted with Medicines Australia in relation to potential revisions to the proposed common format condition, to require data to be available for download in CSV (comma-separated values) file format.

395. On 9 April 2015, Medicines Australia provided a submission reiterating its view that it was sufficient for reports to be made available in a searchable format (such as PDF) and submitting that Medicines Australia does not support a requirement that member companies also provide the transparency reports in a CSV file format. Medicines Australia submitted that:

- reporting in a CSV file format, in addition to a searchable table, is unnecessary. Reporting the information in searchable PDF table form would provide individual patients (and healthcare professionals) with access to sufficient data in a readable and user-friendly way to result in the transparency benefits previously identified while ensuring that the integrity of the healthcare professionals’ personal information is protected from inappropriate use and modification

- CSV file formats do not present data in a meaningful, readable and user-friendly way, and for this reason publishing reports in a CSV file format will not assist the achievement of the benefits identified, instead patients and other healthcare professionals would encounter an incomprehensible ‘dump’ of data

- a requirement to publish data in a CSV file format could prohibit Medicines Australia and member companies from complying with the APPs. This is because publishing a healthcare professional’s personal information in a CSV file format cannot be considered to be for a purpose related to that for which the data was collected because healthcare professionals would not reasonably expect their data to be used or disclosed in a CSV format.

396. Medicines Australia also submitted that CSV file formats do not present data in a useful way and suggested amendments to the ACCC’s draft condition, such as to clarify that reports must be published in a table format as well as a CSV file.

397. The RACGP, the RANZCP, the ASA, Dr Smith, Dr Purssey, Dr Harvey, Professor Del Mar and Professor Morris generally support a requirement to report in Excel or similar format.

**ACCC view**

398. As noted above, the ACCC considers that making information about transfers of value available to, and accessible by, consumers and the public, more generally, in a practical and meaningful way is key to enhancing the likelihood that the benefits of the proposed transparency reporting will be realised.

399. Benefits are likely to arise where consumers are able to access the raw data directly to undertake their own research. Benefits will also arise where the reported information is made available to consumers via communications to them by third parties, such as healthcare professionals, consumer and healthcare professional
bodies, researchers, academics and the media.\textsuperscript{92} The ACCC considers that the transparency reporting will also have other benefits including public confidence in the pharmaceutical industry.

400. As noted elsewhere in this determination, the ACCC considers that an important step to increasing the likelihood that the benefits of transparency reporting are realised would be to make the data accessible via a central reporting system. However, the ACCC recognises that it may take some time for Medicines Australia to investigate and implement such a system.

401. In the absence of a central reporting system, information about the same healthcare professionals will likely be spread across multiple member company websites. In these circumstances, the ACCC considers it necessary to impose a condition to ensure that data is published in a common format. This will assist the public to find, review, collect and extract data from the various member company websites as easily and accurately as possible.

402. Accordingly, the ACCC has decided to impose a condition requiring Medicines Australia to amend its Code to require its member companies to report the individual transparency data in a CSV file available for download (see Condition 2, Attachment B). This will be in addition to reporting the data in a searchable table format. The ACCC considers the imposition of such a condition to be appropriate and necessary to enhance the likelihood of the benefits of transparency reporting.

Concerns raised by Medicines Australia in relation to privacy legislation

403. The ACCC notes Medicines Australia’s concerns about requiring that the information be published in a modifiable and extractable form:

- first, as raised in the 16 March 2015 submission, that making data available in CSV format may mean that member companies have not taken ‘reasonable steps’ to protect the data, in breach of the privacy legislation

- second, as raised in the 9 April 2015 submission, that publishing the information in that format would not be for a purpose related to that for which the data was collected, and therefore could breach privacy legislation.

404. The ACCC appreciates Medicines Australia’s concern to ensure that its members comply with privacy legislation when reporting relevant transfers of value. However, the ACCC does not accept that requiring information to be available in a CSV format, of itself, would cause member companies to breach privacy (or any other) laws.

405. In relation to the first privacy related concern raised by Medicines Australia, the ACCC notes the view of the Australian Privacy Commissioner that the obligation to protect against unauthorised modification does not extend to protecting against modification of the data by a third party who has collected the data from the member company’s website (see paragraph 393 above). The ACCC considers that this deals with the concern raised by Medicines Australia that member companies

\textsuperscript{92} As noted earlier in this determination, to the extent that the third parties are subject to Australian privacy legislation, any such use of the data will need to comply with that legislation.
could be at risk of breaching the APPs if they publish personal information in a format which can be extracted, modified or disclosed by third parties following disclosure on their websites.

406. In relation to the second privacy related concern raised by Medicines Australia, the ACCC notes that, as observed by the Australian Privacy Commissioner (see paragraph 393 above), the information collected from individual healthcare professionals in respect of transfers of value can be disclosed where:

- it is for a purpose related to the primary purpose and
- the individual healthcare practitioner would reasonably expect the information to be used or disclosed for that purpose.

407. The ACCC considers that the purpose of reporting transfers of value (as contemplated under the transparency regime) is to report the data to the public (and thus provide public access to and scrutiny of the reported data). In his submission of 15 May 2014, the Australian Privacy Commissioner considered that the collection of healthcare professionals’ personal information in order to report transfers of value made to individual healthcare professionals for transparency purposes, as required under a code of conduct, could be considered to be related to the original purpose of collection (that is, arranging events or contracting services and making associated payments and transfers of value).

408. It is for member companies to ensure that a healthcare professional would reasonably expect the information to be used or disclosed for that purpose. The steps that member companies take to do so are a matter for them (provided that they comply with Condition 1 of this authorisation).

409. The ACCC does not accept Medicines Australia’s submissions that seek to equate the benefits of transparency via individual reporting referred to in the draft determination with the purposes of disclosure of information under Australian privacy legislation. As noted above, the purpose for which the member companies would be using or disclosing information collected for the primary purpose (related to the provision of the transfer of value) is to report the data to the public and thus provide public access to and scrutiny of the reported data. As outlined in this document, a range of benefits, including (but not limited to) those referred to in the draft determination, are likely to flow from that access and scrutiny.

410. However, even if the benefits of transparency via individual reporting were considered to be the relevant purposes of disclosure of information under Australian privacy legislation, it appears that making information available in CSV format would reasonably be for those purposes.

411. Making the information available in a modifiable, extractable form will assist consumers in collating information about relevant healthcare professionals across a number of member company websites. It will also facilitate third parties in extracting, analysing and interpreting the data with a view to communicating relevant information to consumers and the public more generally in an understandable and meaningful form, with the benefit of:

- giving patients greater transparency over the decisions of their prescribing healthcare professionals

93 The primary purpose being the making of the transfer of value.
• alerting patients to possible influences on their healthcare professionals’ prescribing decisions

• enabling healthcare professionals to inform themselves about matters which may be relevant to their understanding of the position of other healthcare professionals

• deterring member companies from making and healthcare professionals from accepting transfers of value that may raise conflicts of interest

• increasing public confidence in the pharmaceutical industry and its interactions with healthcare professionals.

Other matters

412. In the February consultation, the ACCC proposed requiring common reporting in Microsoft Excel format. The ACCC accepts Medicines Australia’s concerns about restricting its member companies to using a particular proprietary program and, consequently, has selected CSV format. CSV format is compatible with multiple programs and can be easily downloaded into Microsoft Excel and other common spreadsheet formats.

413. The ACCC also notes Medicines Australia’s submission that reporting in CSV format would present data in an unformatted and incomprehensible way. The condition has been clarified to require that information be available for download from CSV format into a spreadsheet program, rather than the report itself being in CSV format.

414. In accordance with the requirements in edition 18 of the Code, the ACCC expects that transparency reports will include the information identified in section 41.3.1 of the Code and be in the table format provided by Medicines Australia.

415. The ACCC does not consider the requirement that the data be made available in the specified CSV format to impose any additional burden on Medicines Australia or its members because they will already be making data available in a character readable PDF table format.

Condition 3: Central reporting system

416. In the draft determination, the ACCC sought submissions on the practical issues and timing for implementing a central reporting system.

417. In the revised proposed conditions of authorisation, which were included in the February consultation, the ACCC set out a requirement on Medicines Australia to use reasonable endeavours to implement a centralised reporting system and to report regularly on progress, as well as other procedural matters for the implementation of the system.

418. Medicines Australia has requested several procedural changes to this proposed condition, including increasing the time for data to be published in a database following the end of a reporting period. Pfizer supports the proposed condition, subject to the amendments proposed by Medicines Australia.
419. The AMA, the RACGP, the RANZCP, Dr Smith, Dr Purssey, Dr Harvey, Professor Del Mar and Professor Morris support the proposed database condition.

ACCC view

420. The ACCC has decided to impose the revised condition included in the February consultation that requires Medicines Australia to use reasonable endeavours to develop and implement a central reporting system and to report six monthly on its progress in doing so (see Condition 3, Attachment B).

421. The condition will also require certain amendments to the Code upon implementation of a central reporting system. Finally, the condition requires that a data field for company name be added since the central reporting system will include data for all member companies. (This is not necessary prior to the implementation of the central reporting system, given that the data in respect of each company is reported only on that company’s website.)

422. The ACCC notes the practical implementation issues identified by Medicines Australia and that Medicines Australia is actively investigating how to establish a central platform for reporting. This includes establishing a working group to investigate these issues. Having regard to the work still to be undertaken by Medicines Australia in respect of developing and implementing a central platform for reporting, the ACCC has decided not to make authorisation conditional upon Medicines Australia implementing a central reporting system by a particular date.

423. In order to comply with Condition 3, the ACCC strongly encourages Medicines Australia to dedicate appropriate resources to developing a central reporting system and implement it as soon as possible. Noting the importance of providing the public with a practical way to access the individual transparency data, the ACCC considers that the development and implementation of a central reporting system should continue to be a matter of the highest priority for Medicines Australia and its members.

424. As discussed at paragraphs 215 to 219, the ACCC considers that a central reporting system is important to ensuring that information about transfers of value made to individual doctors is available to and accessible by the public. In particular, it avoids individuals accessing each member company’s website to get the data. Such availability and accessibility is key to the benefits of reporting the data being realised.

425. While the form of the central reporting system will be informed by the findings of the working group, the ACCC expects that at a minimum the central reporting system should be designed to be easy for consumers to conduct searches relevant to them. The ACCC encourages Medicines Australia to contact the ACCC prior to finalising the user interface of the database to confirm that the design is appropriate.

426. The ACCC notes that the Privacy Commissioner recommended that Medicines Australia conduct a PIA of the proposed central reporting system. Subject to the findings of this PIA, the ACCC also considers that the full data set for each reporting period should be available to the public, via download from the central reporting system (or, if that is not possible, for example, for technical reasons, separately downloadable in CSV format). Having the data available in this way will assist consumers and others in accurately compiling relevant data and
understanding it in context. It will also facilitate accurate research and analysis of the data for the purposes of communicating information about transfers of value made to healthcare professionals to the public, for the benefit of consumers.

427. Subject to Medicines Australia identifying any significant unanticipated issues, the new central reporting system should be operational before Medicines Australia next seeks reauthorisation for the Code. Medicine Australia’s progress in developing and implementing the central reporting system will be an important matter when considering any such future application for reauthorisation by Medicines Australia.

**Condition 4: Public disclosure of reports and retention of records for three years**

428. The Code requires member companies to publish the individual transparency data on their websites for two years from the date of first publication. In the revised proposed conditions of authorisation, in the February consultation, the ACCC consulted on a possible condition to increase this period from two years to three years (the ACCC did not propose imposing such a condition in the draft determination).

429. The submissions in response to the revised conditions support increasing the period for publication of reports. The CHF, the RACGP and Dr Smith support increasing this further to five years.

**ACCC view**

430. The ACCC has decided to impose a condition requiring that reports be published and the data available for download for three years rather than two years (see Condition 4, Attachment B).

431. The ACCC notes that once transparency data is removed from publication, it will effectively be inaccessible to the public (unless a person has saved copies of these old reports). By providing a longer timeframe of reporting data, this will increase the transparency benefits identified at paragraphs 146 to 149.

432. For example, it will assist persons accessing the data to understand the history and context of transfers of value to particular healthcare professionals. It will also make it easier to analyse trends in the relationships between healthcare professionals and member companies over time. These are all matters of relevance to consumers in the context of their relationships with healthcare professionals.

433. Some interested parties have suggested more than three years of data be published. The ACCC considers that three years balances the needs of interested parties and the concerns of Medicines Australia (noted at paragraph 212).

**Condition 5: Amendment of conditions**

434. In the February consultation, the ACCC included a possible condition which would provide a procedure by which Medicines Australia can request non-material amendments to the conditions and for the ACCC to make such amendments. Non-material amendments to the conditions may include amendments to address
practical issues that may arise with the implementation of and compliance with the conditions from time to time.

435. Providing a procedure to deal with such issues will provide a quick and efficient means of addressing issues that may arise in respect of the conditions and which may otherwise impede Medicines Australia’s compliance with the conditions.

436. The AMA, the ASA, Pfizer, Dr Smith, Dr Purssey and Dr Harvey support a condition to allow non-material amendments to the conditions.

**ACCC view**

437. The ACCC has decided to impose the procedural condition in respect of future non-material amendments to the conditions (see Condition 5, Attachment B).

**Length of authorisation**

438. The Act allows the ACCC to grant authorisation for a limited period of time.\(^9^4\) This allows the ACCC to be in a position to be satisfied that the likely public benefits will outweigh the detriment for the period of authorisation. It also enables the ACCC to review the authorisation and the public benefits and detriments that have resulted after an appropriate period.

439. In this instance, Medicines Australia seeks authorisation for five years.

440. Medicines Australia submits that a shorter authorisation period will not allow sufficient time for the new transparency regime to be embedded in the industry and its effectiveness appropriately evaluated, noting the timing of the first publication of the new transparency reports. Medicines Australia submits that a five year authorisation is also appropriate considering the significant time and effort required in updating each edition of the Code, noting however that Medicines Australia will continue to review the provisions of the Code every three years.

441. Interested parties have provided limited feedback on the period of authorisation. As noted above, a number of parties oppose authorisation of edition 18 of the Code in its current form (absent conditions of authorisation). The AMA considers that any public reporting approach implemented by Medicines Australia should be reviewed after a few years of operation and supports a five year authorisation.

442. The ACCC accepts that it will take some time for the new individual transparency regime to be fully operational and for any implementation issues to be smoothed out. In particular, the first transparency reports are not due to be released until 31 August 2016. The ACCC considers that, subject to the conditions of authorisation, the new transparency reporting is an important development that should be given sufficient time to become properly implemented before being reviewed.

443. As such, the ACCC has decided to grant authorisation for five years. In any event, the ACCC notes that Medicines Australia has undertaken to review its Code after three years. Therefore assuming that Medicines Australia seeks reauthorisation for the next version of its Code, it is likely to do so sooner than five years.

\(^9^4\) Subsection 91(1) of the Act.
Scope of the authorisation more broadly

444. The SHPA, the SAMAC, the CHF, Dr Harvey and 25 Individuals submit that the Code should apply more broadly (for example, to all pharmaceutical companies or sponsors including those not in an industry association, health professional organisations, therapeutic goods industry associations and to transfers of value not related to prescription medicines). In a submission following the draft determination, Sanofi also recommends the broader application of the Code to all pharmaceutical companies.

445. The ASA, Dr Harvey and 25 Individuals submit that transparency should be legislated by the Regulatory Policy and Governance Division of the Department of Health, the TGA and the Federal Government.

446. The ASA notes that there are companies that are outside of the Code.

447. Medicines Australia submits that there are significant public benefits associated with developing and complying with voluntary industry codes, including where this reaches beyond statutory regulation. Medicines Australia cannot force companies to join Medicines Australia. However 86 percent of medicines supplied under the PBS are supplied by Medicines Australia members. Further all promotional material (not just that of member companies) must adhere to Medicines Australia's Code. Medicines Australia submits that this issue does not go to whether the ACCC should authorise the Code.

448. The ACCC acknowledges that non-member companies, including generic manufacturers, are required to comply with those provisions of the Code relating to promotional material by virtue of the TGA’s marketing approval letter. However, the ACCC understands that the requirement in the TGA marketing approval letter does not extend to the provision of hospitality at educational events and other aspects of the manufacturer/healthcare provider relationship. Further, potential breaches of the standards in the Code by non-members may not amount to a breach of the TG Act or the Act. The ACCC notes that few complaints against non-member companies are referred to the ACCC for investigation as a potential breach of the Act.

449. Breaches of the standards set by the Code, even by non-member companies, particularly around the provision of inappropriate hospitality to healthcare professionals, impact the reputation of the industry as a whole. Further, inconsistencies in the standards expected of different groups within an industry create an unequal playing field.

450. More concerning is that relationships between pharmaceutical companies not subject to the Code and healthcare professionals are largely unrestricted and not transparent. The ACCC notes the creation of an arms-length and transparent relationship between pharmaceutical companies and healthcare professionals addresses the concern about potential conflicts of interest, particularly that unrestricted relationships may influence the prescribing practices of healthcare providers and may ultimately compromise patient care.

451. The ACCC considers there is significant benefit in regulating the provision of benefits by all manufacturers of therapeutic products including manufacturers of

---

95 In submissions both before and after the draft determination.
generic drugs, prosthetics and other medical devices. However, the ACCC is not able to impose conditions through this authorisation requiring non-members of Medicines Australia to comply with this Code or a similar code. It is however open for other industry associations or groups to develop a code with similar standards of conduct and to seek authorisation from the ACCC, as the GMiA did to increase transparency in the generic pharmaceutical industry (although the GMiA has not sought reauthorisation of its code from the ACCC).

452. The ACCC notes that the authorisation process is not necessarily the appropriate mechanism to redress inconsistencies between various industry codes. The ACCC is required to assess any code for which authorisation is sought on a case by case basis according to the likely public benefits and detriments flowing from that particular code as required by the statutory tests for authorisation. Whether other industry sectors should be required to comply with similar standards as contained in Medicines Australia’s Code is ultimately a decision for those industry sectors or government.

453. In this respect, the ACCC notes the Department of Health Working Group on the Promotion of Therapeutic Products made a number of recommendations for industry, government and healthcare professionals in 2011.96 The report includes a set of high level principles as the basis for strengthening and aligning industry codes of conduct. The Australian Government has stated that its preference is to maintain an emphasis on self-regulation and strongly supports industry’s initiative to harmonise their codes of conduct.

---

5. Determination

The application

On 2 July 2014, Medicines Australia Limited (Medicines Australia) lodged applications for revocation and substitution of new authorisations A91436-A91440 with the ACCC. Applications A91436-A91440 were made using Form FC Schedule 1 of the Competition and Consumer Regulations 2010. The applications were made under subsection 91C(1) of the Act for edition 18 of Medicines Australia’s Code of Conduct (the Code) which sets the standards for the marketing and promotion of prescription pharmaceutical products in Australia.

Medicines Australia seeks authorisation of these arrangements as they may contain a cartel provision and may have the effect of substantially lessening competition within the meaning of section 45 of the Act. The arrangements may also contain an exclusionary provision (within the meaning of section 45 of the Act) that may also be a cartel provision. The conduct may also constitute exclusive dealing.

The net public benefit test

For the reasons outlined in this determination, the ACCC considers that in all the circumstances the proposed arrangements for which reauthorisation is sought are likely to result in a public benefit that would outweigh the detriment to the public constituted by any lessening of competition arising from the conduct.

For the reasons outlined in this determination, the ACCC is also satisfied that the proposed arrangements for which reauthorisation is sought are likely to result in such a benefit to the public that the conduct should be allowed to take place.

However, notwithstanding the above, the ACCC has serious concerns about the transparency reporting regime set out in the Code.

As noted above, the power conferred upon the ACCC to authorise conduct is discretionary. The ACCC may impose a condition in circumstances where, although the relevant public benefit test is met, without the condition, the ACCC would not be prepared to exercise its discretion in favour of authorisation. Where there is limited public detriment (as in the case of the present application) the ACCC can impose a condition to yield a more substantial public benefit or to enhance the likelihood that the public benefit will be realised.

The ACCC has decided to impose conditions upon the exercise of its discretion to authorise the Code in order to address its concerns about the transparency reporting regime.

97 Application by Medicines Australia Inc (2007) ATPR 42-164 at paragraph 106. As noted by the Tribunal at paragraph 126, in exercising that discretion, the ACCC may have regard to considerations relevant to the objectives of the Act

98 Application by Medicines Australia Inc (2007) ATPR 42-164 at paragraph 133.

The ACCC therefore revokes authorisations A91316-A91320 and grants authorisation to applications A91436-A91440 in substitution subject to the conditions as outlined at paragraphs 359 to 437 above and set out in Attachment B.

Conduct for which the ACCC grants authorisation

The ACCC grants conditional authorisation to Medicines Australia for edition 18 of its Code which sets the standards for the marketing and promotion of prescription pharmaceutical products in Australia, subject to the conditions set out in Attachment B.

Further, the authorisation is in respect of edition 18 of the Code as it stands at the time authorisation is granted. Any changes to the Code during the term of the authorisation would not be covered by the reauthorisation (other than the changes required by the conditions of authorisation).

Authorisation does not represent ACCC endorsement of a group or scheme. Rather, it provides statutory protection from legal action for conduct that meets the net public benefit test and that might otherwise raise concerns under the competition provisions of the Act.

This determination is made on 24 April 2015.

Date authorisation comes into effect

This determination is made on 24 April 2015. If no application for review is made to the Australian Competition Tribunal (The Tribunal), it will come into force on 16 May 2015.

This authorisation will expire on 16 May 2020.
Attachment A - Summary of relevant statutory tests

**Subsections 90(5A) and 90(5B)** provide that the ACCC shall not authorise a provision of a proposed contract, arrangement or understanding that is or may be a cartel provision, unless it is satisfied in all the circumstances that:

- the provision, in the case of subsection 90(5A) would result, or be likely to result, or in the case of subsection 90(5B) has resulted or is likely to result, in a benefit to the public; and

- that benefit, in the case of subsection 90(5A) would outweigh the detriment to the public constituted by any lessening of competition that would result, or be likely to result, if the proposed contract or arrangement were made or given effect to, or in the case of subsection 90(5B) outweighs or would outweigh the detriment to the public constituted by any lessening of competition that has resulted or is likely to result from giving effect to the provision.

**Subsections 90(6) and 90(7)** state that the ACCC shall not authorise a provision of a proposed contract, arrangement or understanding, other than an exclusionary provision, unless it is satisfied in all the circumstances that:

- the provision of the proposed contract, arrangement or understanding in the case of subsection 90(6) would result, or be likely to result, or in the case of subsection 90(7) has resulted or is likely to result, in a benefit to the public; and

- that benefit, in the case of subsection 90(6) would outweigh the detriment to the public constituted by any lessening of competition that would result, or be likely to result, if the proposed contract or arrangement was made and the provision was given effect to, or in the case of subsection 90(7) has resulted or is likely to result from giving effect to the provision.

**Subsection 90(8)** states that the ACCC shall not:

- make a determination granting:

  i. an authorization under subsection 88(1) in respect of a provision of a proposed contract, arrangement or understanding that is or may be an exclusionary provision; or

  ii. an authorization under subsection 88(7) or (7A) in respect of proposed conduct; or

  iii. an authorization under subsection 88(8) in respect of proposed conduct to which subsection 47(6) or (7) applies; or

  iv. an authorisation under subsection 88(8A) for proposed conduct to which section 48 applies;
unless it is satisfied in all the circumstances that the proposed provision or the proposed conduct would result, or be likely to result, in such a benefit to the public that the proposed contract or arrangement should be allowed to be made, the proposed understanding should be allowed to be arrived at, or the proposed conduct should be allowed to take place, as the case may be; or

- make a determination granting an authorization under subsection 88(1) in respect of a provision of a contract, arrangement or understanding that is or may be an exclusionary provision unless it is satisfied in all the circumstances that the provision has resulted, or is likely to result, in such a benefit to the public that the contract, arrangement or understanding should be allowed to be given effect to.
Attachment B – Conditions of authorisation

Condition 1: Reporting of all relevant transfers of value

The ACCC requires Medicines Australia to vary the Code, by amending section 41.3.2 as follows, with such amendment to take effect on or before 1 October 2016:

a. deleting the title ‘Informed Consent’ and replacing it with the following:

‘Requirements for Making and Reporting Transfers of Value to Healthcare Professionals’;

b. deleting the words ‘informed consent and’ from the second sentence of the first paragraph; and

c. deleting the second paragraph and replacing it with the following:

‘Companies must not make a transfer of value of a kind referred to in section 41.3.1 unless they have taken appropriate steps to give notice of this disclosure obligation, so that the healthcare professional would reasonably expect the disclosure.’

<table>
<thead>
<tr>
<th>41.3.2 Informed Consent Requirements for Making and Reporting Transfers of Value to Healthcare Professionals</th>
</tr>
</thead>
<tbody>
<tr>
<td>Companies must comply with Australian Privacy legislation (Privacy Act 1988 (C’th)) in regard to the reporting of individual healthcare professional data. Each company must establish a means to ensure informed consent and maintenance of records which comply with Australian Privacy legislation.</td>
</tr>
<tr>
<td>Where recipients of transfers of value cannot be identified for legal reasons, the amount attributable to such transfers must be reported on an aggregate basis by each company. The number of recipients involved must be stated and the aggregate amount attributable to transfers of value to such recipients.</td>
</tr>
<tr>
<td>Companies must not make a transfer of value of a kind referred to in section 41.3.1 unless they have taken appropriate steps to give notice of this disclosure obligation, so that the healthcare professional would reasonably expect the disclosure.</td>
</tr>
</tbody>
</table>

Condition 2: Reporting in common accessible format

The ACCC requires Medicines Australia to vary the Code by amending before 1 October 2015:

a. the fifth paragraph of section 41.3 as follows:

deleting the words ‘The form of reporting must follow the template provided in the Code of Conduct Guidelines’, and replacing with the following:

‘Companies are required to report transfers of value in the following formats:

i. a searchable table to be viewed on a company’s website; and
Condition 3: Central reporting system

Medicines Australia must:

a. upon the authorisation taking effect, use reasonable endeavours to develop and implement a system which will allow the public to access, via a single, searchable source available on the internet, the information contained in the reports of all member companies described in section 41.3.1 (Central Reporting System);

b. within six months of the authorisation taking effect, and at least every six months thereafter until the implementation of a Central Reporting System in accordance with (d) below:

   i. publish a report in the Code of Conduct section of its website identifying the steps taken by Medicines Australia during that reporting period to develop and/or implement a Central Reporting System;

   ii. notify the ACCC upon the report referred to in (i) above being published;

c. prior to implementing a Central Reporting System:

   i. amend the Code by inserting the following words into section 41.3:
‘Companies must provide the reports referred to in section 41.3.1 to Medicines Australia or a third party nominated by Medicines Australia so that the information in those reports can be included in a Central Reporting System within four months of the reporting period to which they relate.’; and

ii. amend the template provided in the Code of Conduct Guidelines for Edition 18 by inserting an additional column in the table titled ‘Company name’.

d. upon implementation of a Central Reporting System and while the authorisation remains in effect:

i. ensure that all reports referred to in (c) above are included in the Central Reporting System, within six months of the end of the reporting period to which they relate;

ii. maintain and update the Central Reporting System; and

iii. ensure that information contained in the Central Reporting System remains accessible by the public for a period of at least three years.

Condition 4: Public disclosure of reports and retention of records for three years

The ACCC requires Medicines Australia to vary the Code by amending before 1 October 2015 section 41.3.4 by deleting the word ‘two’ and replacing with the word ‘three’.

Condition 5: Amendment of conditions

a. Medicines Australia may apply in writing to the ACCC for a non-material amendment to these conditions.

b. Such applications must:

i. state the nature of, and reasons for, the amendment sought;

ii. be accompanied by supporting evidence.

c. The ACCC may request from Medicines Australia any additional information required by the ACCC to assess the application for amendment.

d. The ACCC will consider the application for amendment and, in its absolute discretion, decide whether or not to make a non-material amendment to the conditions and the nature and form of any amendment. The ACCC will notify Medicines Australia, in writing, of its decision.

e. If the ACCC decides to amend the conditions, the amendment will take effect from a date determined by the ACCC.